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ABBREVIATIONS
aa amino acid
ARF alternative reading frame
ATCC American Type Culture Collection
CIP cdk-interacting protein
DP dimerization partner
EGF epidermal growth factor
FGF fibroblast growth factor
GDP guanosine diphosphate
Grb growth-factor receptor bound protein
GRF guanine nucleotide releasing factor
GRP guanine nucleotide releasing protein
GTP guanosine triphosphate
Hsp heat shock protein
IGFR insulin-like growth factor receptor
INK inhibitor of kinase
IRS insulin receptor substrate
kd kilodalton
NGF nerve growth factor
PCNA proliferating cell nuclear antigen
PDGF platelet-derived growth factor
TAK TGF-β-activated kinase
TGF-β transforming growth factor beta
TIMP tissue inhibitor of metalloproteases
WAF wild-type p53-activated fragment
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SUMMARY
Ras-proteins function as relays which transmit signals from the cell's exterior to
intracellular signaling pathways. The best-characterized of these pathways is the
mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK)
pathway, which is initiated by mitogenic growth factors and leads to cell proliferation.
The MAPK/ERK pathway is thought to promote cell cycle progression by regulating
cyclins and cyclin kinase inhibitors (CKIs), thereby increasing the amount of active
cyclin dependent kinase (Cdk) complexes. Active Cdks are "cell cycle engines" that
phosphorylate, among other targets, the retinoblastoma protein (Rb). Rb
phosphorylation liberates Rb-bound transcription factor E2F to activate transcription
of genes required for S-phase entry.
Oncogenic mutations of Ras have been found in 30% of human cancers, which
indicates the importance of Ras for normal cell growth. The mutations render Ras
constitutively active even in the absence of mitogenic stimuli. In cell culture systems,
however, oncogenic Ras transforms immortal cells but arrests the growth of primary
cells. The differential outcome may be determined by the function of cell cycle
regulators. We have therefore analyzed the effects of c-Ha-Ras oncogene and
mitogenic growth factors and their activated pathways on cell cycle regulation,
especially on Rb and p21 CKI (p21) cell cycle proteins.
During the course of the work, mouse fibroblast clones were generated expressing
high levels of human Rb. The transformation ability of Ras was analyzed by
transfecting these cells with oncogenic c-Ha-Ras, followed by analysis of cell
morphology, soft agar growth and protein levels of exogenous Ras and Rb. A high
level of Rb was shown to prevent Ras-transformation, and gradual transformation
coincided with a decrease in Rb and an increase in Ras protein levels (I). The Ras-
effects were also studied in Rb-expressing mouse fibroblasts conditionally expressing
c-Ha-Ras. Induction of Ras-expression rapidly downregulated Rb at the
posttranscriptional level, and transformed these cells. Repression of Rb by Ras
required growth factors, suggesting a complicated interplay between Ras and Rb (II).
Further addressing the effects of Ras on the cell cycle, we analyzed the effects of
conditional and transient c-Ha-Ras expression on p21 in mouse fibroblasts and
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monkey kidney cells. Conditional expression of Ras induced p21 translation via the
MAPK/ERK pathway, while transient, high-level Ras expression activated p21
transcription via two Sp1 binding sites near the transcription start site (III). To link the
growth factor regulation of p21 to Ras-activated pathways, we investigated FGF-2-,
PDGF-, and TGF-β-mediated p21-induction. For this, we used a specific MAPK
kinase (MEK) inhibitor and mouse fibroblasts conditionally expressing either
oncogenic Ras or dominant negative Ras that blocks endogenous Ras-function. The
results suggest diverse growth factor-activated pathways since p21 induction by FGF-
2 does not exclusively require Ras or MEK, while PDGF acts through MEK but not
Ras. TGF-β-induction of p21 was shown to be relatively slow and to occur via both
Ras and MEK (IV). These studies extend what is known of responses of the negative
cell cycle regulators Rb and p21 CKI to mitogenic stimuli.
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INTRODUCTION
Normal cell growth is governed by the balanced action of growth stimulatory and
inhibitory pathways as well as pathways regulating cell death. Proliferation by itself is
necessary but not sufficient for cellular transformation and therefore malfunction of
several pathways is required for malignant conversion. A vast number of mutated
genes have been identified in human cancers. These genes are categorized into classes
of proto-oncogenes, tumor suppressors, and DNA repair genes. Mutational activation
of proto-oncogenes and inactivation of tumor suppressors are accompanied by
increased proliferation and/or cell survival whereas inactivation of DNA repair genes
does not directly affect cell growth but rather leads to an accelerated appearance of
deteriorating mutations in the genome. In addition to hereditary or acquired defects in
growth regulators and DNA repair genes, genetic differences in responses to
environmental and cellular stress, e.g. the capacity to metabolize carcinogenic agents
or free radicals influence cancer incidence.
Studies on the preference of different mutations and their order of appearance in
cancer have proved that each tumor type shows a unique combination of mutations
appearing in a unique order. However, accumulation of mutations that enhance
proliferation and mutations that silence the growth inhibitory and suicidal (apoptotic)
signals induced by excessive proliferation give the cell no other choice but to
proliferate. In contrast to primary tumor formation that may occur via a diverse set of
accumulating genetic lesions, metastatic properties, the major determinant of cancer
lethality, are gained rather similarly in different cancers. Only about 0.05% of
circulating tumor cells can actually form metastases [Woodhouse et al., 1997]. This
requires an increased capacity to attach to neighboring cells and extracellular matrix
via adhesion molecules and receptors as well as invasive and migratory properties via
production of matrix proteases and chemotactic cytokines. In new surroundings,
cancer cells must also possess the ability to form colonies and induce new blood
vessels for oxygen and nutrient supply. In addition, the new environment must
provide the metastatic cell appropriate endothelial properties as well as suitable
growth factors and extracellular matrix.
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In this study I have analyzed factors involved in malignant transformation of mouse
fibroblasts. Since the deranged action of both positive and negative growth regulators
is required in cancer, I have investigated, in cell culture conditions, the effects of
strong growth promoting signals, i.e. oncogenic Ras and mitogenic growth factors, on
the negative growth regulatory proteins retinoblastoma (Rb) and p21 cyclin kinase
inhibitor (p21).
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REVIEW OF THE LITERATURE
Cell cycle and G1 restriction point control
The normal autosomal cell cycle consists of four phases: A DNA synthesis phase (S)
and cell division phase (M) separated by two gap phases (G1 and G2). Nondividing
cells are resting in the G0 phase, from where they can be driven into the cycle if
required [Hamel and Hanley-Hyde, 1997]. The core of the cell cycle machinery
consists of cyclin dependent kinase (Cdk) complexes, the activation of which is
strictly regulated during the cell cycle. Each cell cycle phase exhibits a unique pattern
of active Cdks which conduct the cycle by coordinately phosphorylating their
substrates [Hamel and Hanley-Hyde, 1997]. Cdks are partly activated by binding to
cyclin subunits, the levels of which oscillate in the course of the cell cycle promoting
periodic Cdk-functions. However, an additional 80-300-fold increase in Cdk-activity
is achieved by phosphorylation of its conserved threonine residue (residue 161 in
Cdc2) by Cdk-activating kinase (CAK) [Morgan, 1996; Scalfani, 1996]. Inactivation
of Cdks takes place partly by phosphorylation of tyrosine and threonine residues at the
catalytic cleft, while dephosphorylation of these residues by Cdc25 phosphatases
activates Cdks [Lew and Kornbluth, 1996]. Additionally, inactivation of Cdks may
occur by binding of cyclin kinase inhibitors (CKIs) of the INK4 family (p15Ink4b,
p16Ink4a, p18Ink4c and p19Ink4d) or the p21 family (p21Cip1/Waf1, p27Kip1 and p57Kip2)
[Sherr, 1996].
Cycling cells are continuously monitoring both internal and external conditions and, if
required, their cell cycle progression can be halted at so-called cell cycle checkpoints
by arresting signals from outside or from inside the cell [Sherr, 1996]. The cell cycle
checkpoints are also thought to ensure that the previous cell cycle phase is completed
successfully before the next begins, and that each phase occurs only once per cycle.
Otherwise, cell size or ploidy would be changed [Elledge, 1996]. The most widely
studied checkpoint is the G1 restriction point in the border of the G1 and S phases. Its
deregulation in cancer is rather a rule than an exception [Sherr, 1996]. In normal cells,
G1-progression is dependent on mitogenic signals until the G1 restriction point is
reached [Sherr, 1996]. Mitogenic stimuli induce cyclin D expression starting at mid-
G1 and peaking at the G1/S transition [Matsushime et al., 1994] (see Figure 1). In
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addition to cyclin D, growth factor signals also regulate other determinants of Cdk-
activity including the levels of CKIs, especially of p27Kip1 (p27), and Cdc25
phosphatases [Steiner et al., 1995; Coats et al., 1996]. These events lead to activation
of Cdk4 and Cdk6 that phosphorylate substrates including the retinoblastoma protein
(Rb) and promote G1 progression [Bartek et al., 1997]. After the restriction point at
late G1, S-phase entry occurs independently of extracellular signals probably due to
upregulation of cyclin E, which binds Cdk2. Cyclin E expression is induced by the
E2F transcription factor after phosphorylation and inactivation of Rb [Sherr, 1996]
(see Figure 1).
In addition to extracellular signals, changes in the internal milieu and the genome also
regulate cell cycle progression [Sherr, 1996]. One of the best-known sensors and
regulators of the internal cell cycle control pathway is the tumor suppressor p53
whose upregulation after DNA-damage leads to growth arrest at least partly via
induction of the CKI p21Cip1/Waf1 (p21) (see Figure 1) [El-Deiry et al., 1993].
Inactivation of p53 is common in cancer and may lead to genomic instability and
increased mutation frequency [Levine, 1997].
G0
G1
S
Cdk4/6/cyD Cdk2/cyE
E2FE2F
Rb
RbP
Mitogens
Intracellular stress pathways
p27
p21
p53
Figure 1. Regulation of the G1/S cell cycle transition by extracellular mitogenic signals
and intracellular stress pathways. Modified from Sherr [1996]. Mitogenic stimulation
downregulates p27 CKI and induces cyclin D1 expression, thereby increasing the Cdk4/6
activities. These Cdks phosphorylate Rb and liberate E2F transcription factor to activate
expression of genes required in S-phase entry. Among these genes is cyclin E, which further
enhances the phosphorylation of Rb by Cdk2. The tumor suppressor p53 blocks the cell cycle
by inducing 21 CKI that inhibits various Cdk complexes. RbP, phosphorylated Rb; cyD,
cyclin D; cyE, cyclin E; p21, p21Cip1/Waf1 CKI and p27; p27Kip1CKI.
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Ras-proteins, important transmitters of extracellular signals
The RAS family
The mammalian RAS family consists of three highly conserved genes H-RAS, K-RAS
and N-RAS [Lowy and Willumsen, 1993]. The RAS genes encode four 21 kd (188-189
aa) guanine nucleotide binding proteins (H-Ras, K-RasA, K-RasB and N-Ras) that
transmit extracellular signals inside the cell. Their conservation is highlighted by the
fact that the amino acid sequence of H-Ras is identical in the mouse and humans
[Lowy and Willumsen, 1993]. The catalytic region of Ras, spanning residues 1-164,
as well as the last four aa involved in posttranslational modification are highly
homologous among the family members [Lowy and Willumsen, 1993], whereas
residues 165-185 are dissimilar and therefore named the hypervariable region [Grand
and Owen, 1991]. The hypervariable region of each Ras-family member is highly
conserved among species and may be required for their unique functions [Grand and
Owen, 1991]. At the molecular level, no major differences in function of H-Ras, K-
Ras and N-Ras have been detected. They show, however, differential expression in
many adult tissues as well as during development [Furth et al., 1987; Leon et al.,
1987] and differentiation [Delgado et al., 1992]. Unlike H-RAS and N-RAS knock-out
mice, mice lacking K-RAS do not survive to birth due to liver defects and anemia,
indicating the indispensability of K-Ras in embryonal development [Johnson et al.,
1997; Koera et al., 1997]. Further, mutations of different RAS genes have different
capacities to transform cells and they exhibit unique tumor spectra [Bos, 1989; Maher
et al., 1995]. N-RAS mutations are highly prevalent in myeloid disorders, H-RAS in
bladder carcinoma and K-RAS in various adenocarcinomas [Bos, 1989].
Activation of H-Ras
H-Ras is attached to the inner surface of the plasma membrane after a series of
posttranslational modifications of the carboxy-terminus (C-terminus) including
farnesylation and carboxymethylation of cysteine 186, proteolytic cleavage of the last
three amino acids, and palmitylation of the C-terminal cysteines 181 and 184 [Grand
and Owen, 1991; Marshall, 1993]. Membrane association is necessary for Ras-
function, and the ability of Ras to transform cells is prevented by inhibiting the
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posttranslational modifications and thereby membrane attachment of Ras [Jackson et
al., 1990].
The major determinant of membrane-bound Ras activity is its ability to bind guanine
nucleotides GDP and GTP, GTP-bound Ras being biologically active (see Figure 2)
[Satoh et al., 1992]. Guanine nucleotide binding causes vast conformational changes
in Ras structure especially in the regions called switch 1 (residues 30-38) and switch 2
(residues 60-76). The switch 1 area is part of the Ras effector domain (residues 26-48)
essential e.g. for Ras-transformation [Marshall, 1993]. GTP-binding of Ras is induced
by growth factors like PDGF, EGF, FGF, NGF and insulin, through their tyrosine
kinase receptors, as well as by TGF-β and lymphokines [Satoh et al., 1992; Hibi and
Hirano, 1998]. In addition, activation of G protein-coupled receptors [Gutkind, 1998],
intracellular non-receptor tyrosine kinases like Src and Abl [Satoh et al., 1992], as
well as calcium and diacylglycerol activate Ras [Ebinu et al., 1998].
Mediators of Ras activation are guanine nucleotide exchange factors (GEFs), also
called guanine nucleotide releasing proteins (GNRPs) or guanine nucleotide
dissociation stimulators (GDSs) that induce GDP dissociation and thereby GTP
binding, since the intracellular concentration of GTP is significantly higher than that
of GDP (see Figure 2). The first characterized mammalian RasGEFs were Sos1/2 and
Cdc25/RasGRF [Satoh et al., 1992; Boguski and McCormick, 1993]. Recently, the
existence of yet another RasGEF, RasGRP, in the nervous system has been confirmed
[Ebinu et al., 1998]. EGF signaling can be used as an example of Ras activation. EGF
binding activates the EGF receptor which then binds the adapter protein Grb2
complexed with Sos, thereby bringing Sos near Ras for nucleotide exchange and
activation [Lowenstein et al., 1992; Buday and Downward, 1993]. However, other
receptor (e.g. IGFR) or non-receptor (e.g. v-Src) tyrosine kinases may activate Ras via
additional molecules such as Shc and IRS1 [Schlessinger, 1993; Pronk et al., 1994].
Inactivation of H-Ras
Ras proteins are inactive in their GDP-bound form. They possess a low intrinsic
capacity to hydrolyze bound GTP to GDP, which is greatly enhanced by GTPase
activating proteins (GAPs) leading to a more rapid inactivation of Ras (see Figure 2)
[Polakis and McCormick, 1992]. So far, two mammalian RasGAPs have been
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characterized, which are p120GAP [Vogel et al., 1988] and neurofibromin 1 (NF1)
[Martin et al., 1990]. However, evidence for additional RasGAPs exists [Maekawa et
al., 1994]. Initially, it was believed that GAPs function only as negative regulators of
Ras. However, since the GAPs were shown to bind to the region overlapping the Ras
effector domain, there has been an untiring search for possible effector functions for
GAPs [Polakis and McCormick, 1992; Marshall, 1993]. Recently indeed, p120GAP
has been shown to mediate some aspects of Ras signaling and it may also link Ras to
other intracellular pathways (discussed later). So far, NF1 has no identified Ras
effector functions. However, it may play a Ras-independent role in tumor suppression
since its overexpression inhibits tumor formation without affecting Ras GTPase
activity [Li and White, 1996].
Inactive 
Ras
GDP
Active
Ras
GTP
GDP GTP
Pi
activation
inactivation
GEFs
GAPs
Activation 
signal
Figure 2. Ras activation and inactivation steps. Modified from Polakis and McCormick
[1992]. Activating signals bring GEFs near Ras to promote GDP-dissociation and GTP-
binding of Ras. Ras inactivation occurs by binding to GAP proteins that increase the GTPase
function of Ras. GAPs; GTPase activating proteins, GEFs; guanine nucleotide exchange
factors, GDP; guanosine diphosphate, GTP; guanosine triphosphate, Pi; a phosphate group.
Cellular transformation by Ras
RAS mutations have been found in around 30% of human cancers [Bos, 1989]. H-Ras
and K-Ras were first identified as viral (v-Ras) oncoproteins of Harvey and Kirsten
murine sarcoma viruses, respectively, capable of cellular transformation [Ellis et al.,
1981], whereas the N-Ras oncoprotein was identified in a neuroblastoma cell line
[Shimizu et al., 1983]. Several alternative modifications of cellular Ras (c-Ras)
provide transforming capacity by increasing the amount of active GTP-bound Ras
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independently of extracellular signals. The most common oncogenic alterations are
single amino acid substitutions at positions 12, 13, 59 or 61 rendering Ras resistant to
GAP-activity, leading to decreased GTP hydrolysis and constitutive activation
[McCormick, 1989; Boguski and McCormick, 1993]. In some cases, however,
increased expression of the normal RAS gene by gene amplification [Pulciani et al.,
1985] or by the presence of a strong promoter element [Chang et al., 1982] may
transform cells. In addition, mutations in the last intron of H-RAS that abolish
alternative splicing, normally downregulating H-RAS expression, can be a mechanism
for oncogenic activation [Cohen and Levinson, 1988; Cohen et al., 1989].
Immortal cells, including mouse fibroblast NIH 3T3 cells, are easily transformed by
oncogenic Ras alone [Newbold and Overell, 1983]. However, to transform primary
cells, Ras requires the co-operative action of e.g. c-Myc or D-type cyclins [Land et al.,
1983; Lovec et al., 1994], or simultaneous expression of viral oncoproteins including
simian virus 40 (SV40) T antigen, adenovirus E1A or human papilloma virus E7
[Hicks et al., 1991; Lin et al., 1995; Peacock et al., 1995]. Alternatively, inactivated
tumor suppressor genes like p53 or p16 together with oncogenic Ras promote the
transformation of primary cells [Hicks et al., 1991; Serrano et al., 1997].
Ras can activate various nuclear factors that regulate mitogenic responses (discussed
below) as well as expression of proteins that promote transformation and metastasis.
Ras-transformed cells exhibit increased levels of the calcium binding proteins
calcyclin and osteopontin, and degradative enzymes including type IV collagenases
and cathepsins L and B, while expression of their inhibitors, TIMPs and cystatins, is
decreased [Chambers and Tuck, 1993]. In addition, α-integrin and fibronectin
required in cell adhesion as well as α-actin are repressed by Ras [Chandler et al.,
1994; Ye et al., 1996; Bushel et al., 1995]. These changes may increase motility and
invasiveness of Ras-transformed cells. Ras also upregulates the expression of growth
factors like TGF-α and TGF-β that enhance proliferation and metastasis in an
autocrine fashion [Berkowitz et al., 1996; Cosgaya and Aranda, 1996]. Ras-
transformation is often accompanied with deficient cell differentiation, e.g. muscle
cell differentiation is prevented by v-Ras with concomitant repression of muscle cell
differentiation genes such as myogenin [Russo et al., 1997]. In addition, Ras is shown
to promote angiogenesis by inducing the expression of vascular endothelial growth
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factor/vascular permeability factor VEGF/VPF [Rak et al., 1995; Enholm et al.,
1997]. Increased expression of ornithine decarboxylase (ODC), transin, and glucose
transporter [Sistonen et al., 1989] as well as cyclin D, which promotes premature S-
phase entry (discussed below) [Liu et al., 1995], are also associated with Ras-
transformation. Yet one way to enhance cellular tumorigenicity may be the ability of
Ras to cause chromosomal and genetic aberrations by unknown mechanisms that are
speculated to include alterations in DNA metabolism, saturation of DNA repair
systems or premature S-phase entry [Denko et al., 1994].
Ras and cell cycle regulation
Oncogenic Ras often deregulates the S-phase entry [Liu et al., 1995], and therefore
cellular Ras is likely to function as part of the cell cycle control. Indeed, the role of
Ras in cell proliferation and cell cycle control is highlighted by several findings. Ras
is activated by serum and various growth factors [Satoh et al., 1992], and its
expression in quiescent immortal mouse fibroblasts leads to cell cycle entry and
transformation [Stacey and Kung, 1984]. Treatment of quiescent cells with
neutralizing Ras-antibody, in contrast, prevents S-phase entry by serum [Mulcahy et
al., 1985]. Besides the growth factor-induced Ras activation, Ras becomes activated
independently of extracellular signals in the mid-G1-phase [Taylor and Shalloway,
1996]. Dobrowolski et al. [1994] have elucidated the involvement of Ras activity at
multiple steps during the G1-phase and S-transition. These results suggest an
important role for Ras in cell cycle entry.
The exact mechanisms of Ras-action in cell cycle regulation are largely unknown.
However, recently cyclin D1, a regulatory subunit of several Cdks, was shown to be
upregulated in Ras-transformed cells (see Figure 3) [Filmus et al., 1994; Liu et al.,
1995; Winston et al., 1996] leading to an increased proliferation rate [Filmus et al.,
1994] or shortened G1-phase of the cells [Liu et al., 1995; Winston et al., 1996]. These
effects are reversed by Cyclin D1 antisense oligonucleotides [Filmus et al., 1994; Liu
et al., 1995]. Ras activates Cyclin D1 transcription [Albanese et al., 1995], and
dominant negative Ras prevents serum induction of cyclin D1 protein [Aktas et al.,
1997]. Ras-effectors including Raf and MEK have also been shown to increase Cyclin
D1 expression [Lavoie et al., 1996]. Probable mediators of cyclin D1 induction by
Ras are Ap-1-complexes composed of Jun and Fos transcription factors. Their levels
Review of the Literature
19
and activities are regulated by Ras [Sistonen et al., 1989; Derijard et al., 1994; Mechta
et al., 1997], and deletion of Ap-1 sequences in the Cyclin D1 promoter abolishes
induction by Ras [Albanese et al., 1995].
Another possible downstream effector of Ras-induced cell cycle changes is p27Kip1
CKI (p27) (see Figure 3). Although Ras leads to an increased level and Cdk-binding
of cyclin D1 in quiescent cells, the formed Cdk-complexes are inactive in many cases
and unable to promote cell cycle progression due to bound p27 [Winston et al., 1996].
Only after growth factor stimulation, is p27 downregulated and S-phase entry occurs
[Winston et al., 1996]. Similarly, activation of MEK in serum-starved cells increases
the amount of inactive Cdk/cyclin D complexes, since p27 is not degraded as it is in
response to serum [Cheng et al., 1998], though also contrasting results have been
obtained [Greulich and Erikson, 1998]. Although Ras is unable to repress p27 levels
in the quiescent state, the Ras pathway seems to be required for p27 downregulation
by serum [Takuwa and Takuwa, 1997]. Dominant negative Ras inhibits activation of
Cdk2 and Cdk4 by serum, Cdk4-activity being prevented mostly due to a lack of
cyclin D accumulation whereas Cdk2 activation is blocked by a lack of p27
downregulation as well as a lack of its shift from Cdk2 to Cdk4 complexes [Aktas et
al., 1997]. The results imply both Ras dependent and independent regulation of p27.
Since collaboration of Ras and Myc in quiescent cells increases Cdk-activity with
concomitant p27 downregulation and S-phase entry [Leone et al., 1997], Ras-
independent Myc-regulation may contribute to the cell cycle regulation. Myc also
activates transcription of the Cdc25A phosphatase and cyclin E [Galaktionov et al.,
1996; Perez-Roger et al., 1997] (see Figure 3). Ras is not required for the S-phase
entry of retinoblastoma (Rb) knockout cells [Leone et al., 1997], suggesting that Rb is
a downstream effector of Ras (discussed later). Other links between Ras and the cell
cycle machinery may include Raf-induced phosphorylation and activation of Cdc25A
required for Cdk activation [Galaktionov et al., 1995] (see Figure 3). The connections
of Ras and p21 CKI in cell cycle regulation are discussed below (see Figure 3).
Ras in differentiation, growth arrest and senescence
Although Ras was originally characterized as a protein with mitogenic and
transforming potential, it has been later shown to have strikingly diverse effects on
cell growth. Besides proliferation and transformation, Ras has been implicated in
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cellular events including differentiation, growth arrest, and senescence.
Microinjection of H-Ras oncoprotein into mouse pheochromocytoma PC12 cells leads
to reversible neuronal differentiation and growth arrest [Bar-Sagi and Feramico,
1985]. Similarly, NIH 3T3-L1 cells that are normally differentiated into adipocytes by
insulin or IGF-1, are differentiated by oncogenic Ras in the absence of these growth
factors with concomitant growth arrest [Benito et al., 1991]. Further, expression of
oncogenic H-Ras results in growth arrest of rat Schwann cells whereas these cells are
transformed when Ras co-operates with SV40 large T antigen, adenoviral E1A, or
Myc, and growth arrest is absent [Ridley et al., 1988]. Similar results have been
obtained in these cells with Raf-1 [Lloyd et al., 1997], which causes growth arrest via
p53-dependent induction of p21 cyclin kinase inhibitor (p21) without affecting p27
levels [Lloyd et al., 1997]. In murine fibroblasts moderate Raf expression is
accompanied by cell cycle progression whereas a robust Raf signal leads to p53-
independent accumulation of p21 and p21-dependent cell cycle arrest, a phenomenon
not seen in p21-/- cells [Sewing et al., 1997; Woods et al., 1997] (see Figure 3).
S phase 
Growth factor signaling
Ras
Raf
Cdc25
c-Myc
cyclin D1
Cdk4
cyclin E
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Figure 3. Regulation of the cell cycle by Ras. Modified from Kerkhoff and Rapp [1998].
Various growth factors activate the Ras/Raf pathway. Moderate activation leads to S-phase
entry via increased expression of cyclin D1 and Myc, degradation of p27 by Ras and Myc,
and activation of Cdc25. In contrast, excessive stimulation of the Ras/Raf pathway may cause
growth arrest by upregulation of p21.
Review of the Literature
21
Although Ras-induced growth arrest seems to partly rely on p21, also other regulators
are required. In primary human and rodent fibroblasts oncogenic H-Ras induces
accumulation of negative growth regulators p53, p21 and p16Ink4a (p16) and cellular
senescence with irreversible growth arrest, while growth arrest is prevented by
coexpression of E1A or by disruption of p53 or p16 function [Serrano et al., 1997].
Expression of p16 in rat immortal fibroblasts inhibits the Ras-induced cell
proliferation as well as transformation caused by the joint action of Ras and Myc
[Serrano et al., 1995]. This inhibition is dependent on functional Rb, suggesting that
p16 and Rb act in the same pathway [Serrano et al., 1995]. The pathway leading from
Ras to induction of p53, p21 and p16 and senescence has been recently identified as
the Raf/MEK/MAPK pathway [Lin et al., 1998] (discussed later). Activation of the
MAPK pathway may lead to opposing growth effects; cell senescence as well as
proliferation or transformation, but the factors specifying the response have so far not
been identified. Determinants of the final outcome are suggested to include
downstream cell cycle regulators but also the strength and duration of the
Ras/Raf/MAPK signaling, as seen in the case of Raf [Woods et al., 1997].
The mitogen-activated protein kinase pathways
Pathways downstream of Ras have recently been resolved. A major step was the
identification of extracellular signal-regulated kinases (ERKs), activated by various
extracellular stimuli [Crews et al., 1992], and the Ras-involvement in their activation
[de Vries-Smits et al., 1992]. In addition to several ERK pathways, there are at least
two other mitogen-activated protein kinase (MAPK) pathways in mammalian cells,
named the Jun N-terminal kinase (JNK) and p38 pathways [Waskiewicz and Cooper,
1995]. ERKs are activated via tyrosine kinase receptors, heterotrimeric G-protein-
coupled receptors, and cytokine receptors, and regulate cell proliferation and
differentiation [Lewis et al., 1998]. In contrast, JNK and p38 are activated in cellular
stress and are therefore called stress-activated protein kinases (SAPKs) [Minden et al.,
1994; Kyriakis and Avruch, 1996].
The basic principle of signaling via each MAPK pathway is similar [Lewis et al.,
1998] (see Figure 4). Extracellular factors stimulate small GTPase proteins such as
Ras that activate MAPK kinase kinases (also called MKKKs). MKKKs thereafter
activate MAPK kinases (also called MEKs 1-7) by serine phosphorylation that in turn
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activate MAPKs (ERKs 1-5, JNK-α, -β, -γ, p38-α, -β, -γ, -δ) by sequential tyrosine
and threonine phosphorylation [Dhanasekaran and Reddy, 1998; Lewis et al., 1998].
Activated MAPKs then phosphorylate several cytoplasmic and nuclear target proteins
including cytoskeletal proteins, protein kinases and other signaling components and
transcription factors that eventually regulate events such as cell growth, proliferation,
differentiation and cell death [Lewis et al., 1998]. As well as the Raf-family (Raf-1,
A-Raf and B-Raf) that activate ERK1 and ERK2 via MEK1 and MEK2, several
families of MKKKs have been identified: MEKKs (e.g. MEKK1-5 and TAK1) and
multilineage protein kinases (MLKs) that activate preferentially SAPKs by MEK3, 4,
6 and 7, and, finally, Mos that is involved in meiosis through the ERK pathway
[Kosako et al., 1994; Lewis et al., 1998] (see Figure 4).
Activation
Serine phosphorylation
Tyrosine/threonine phosphorylation
GTPases
(Ras,Rho)
MKKK/MEKK
(Raf,MEKK1-5,
Tak1,MLK,Mos)
MEK
(1-7)
MAPK
(ERKs,JNKs,p38)
Cytoplasmic targets Nuclear targets
Figure 4. Schematic drawing of the MAPK cascades. Modified from Lewis et al. [1998].
The activation of small GTPase proteins such as Ras leads to activation of MAPK cascades.
The MAPKs are activated via the MKKKs and the MEKs. The activated MAPKs
phosphorylate several cytoplasmic substrates, then translocate into the nucleus and
phosphorylate nuclear targets. ERK; extracellular signal-regulated kinase, JNK; Jun N-
terminal kinase, MAPK; mitogen-activated protein kinase, MEK; MAPK kinase,
MEKK/MKKK; MAPK kinase kinase. In brackets, there are a few representatives of each
group of proteins/kinases along the MAPK pathway.
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Ras and the mitogen-activated protein kinase pathways
Ras strongly activates the pathway consisting of Raf, MEK1/2 and ERK1/2 whereas
other small GTPases e.g. Rac and Cdc42 are involved in the JNK and p38 pathways
activated upon cellular stress [Kyriakis and Avruch, 1996]. Plenty of evidence
connects the ERK pathway to Ras-induced proliferation, differentiation and
transformation signals. Ras expression leads to growth factor-independent activation
of ERKs while dominant negative Ras, Ras(Asn-17) that competes with the
endogenous Ras for upstream signaling molecules but is unable to propagate the
signal downstream, prevents ERK activation by growth factors including FGF, NGF,
EGF, PDGF, and TGF-β [de Vries-Smits et al., 1992; Thomas et al., 1992; Wood et
al., 1992; Burgering et al., 1993; Gardner and Johnson, 1996; Hartsough et al., 1996].
Similarly, activation of Raf by EGF is abolished by dominant negative Ras [Lange-
Carter and Johnson, 1994], and dominant negative Raf prevents ERK activation by
growth factors and Ras [Schaap et al., 1993]. Ras is required for membrane
localization of Raf although this is not enough for Raf activation [Leevers et al.,
1994]. Additional steps that are still fairly unclear, including at least phosphorylation
and complex formation with proteins like 14-3-3 and Hsp90, are required [Wartmann
and Davis, 1994; King et al., 1998; Tzivion et al., 1998]. Constitutive active Raf,
located in the plasma membrane, leads to transformation and differentiation that
resemble Ras-effects [Leevers et al., 1994]. Similarly to Ras and Raf, constitutively
active MEK leads to growth factor-independent differentiation in PC12 cells and to
transformation in NIH 3T3 cells whereas dominant negative MEK inhibits
differentiation and reverts Ras-induced transformation [Cowley et al., 1994; Mansour
et al., 1994]. Further, activated MEK causes similar cell cycle changes as Ras, namely
accelerated S-phase entry via regulation of cyclin D1 and p27 [Greulich and Erikson,
1998], as well as induction of p53, p21 and p16 and cellular senescence [Lin et al.,
1998].
In addition to the cell cycle proteins discussed above, other targets of the ERK
pathway include transcription factors of the Ets-family and components of the Ap-1
complex as well as Myc [Lewis et al., 1998]. Among the substrates are also protein
kinases Mnk1 and Mnk2, which phosphorylate the eukaryote initiation factor 4E
required in translational control, and MAPKAP-1-3, which phosphorylate glycogen
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synthase kinase 3, CREB, c-Fos, serum response factor (SRF), and actin capping
protein Hsp27 [Lewis et al., 1998]. In addition, cytoskeletal proteins like caldesmon,
dystrophin and Tau, signaling components such as Sos, EGFR and phospholipase A-
2, as well as topoisomerase II α are regulated by the ERK pathway [Lewis et al.,
1998].
In addition to the ERK pathway, Ras may be required for some aspects of SAPK
signaling as well (see Figure 5). Activation of JNK by ultraviolet radiation is
dependent on Ras [Derijard et al., 1994; Adler et al., 1996] and, recently, inhibition of
JNK function was observed to prevent Ras-transformation [Clark et al., 1997]. In
addition, EGF-induced and MEKK1/JNK-mediated c-Jun transcription seems to
require both Ras and a Rho-family member, Rac [Clarke et al., 1998]. It is possible
that Rho-family GTPases connect Ras to SAPK pathways (see below).
The complexity of the MAPK pathways is increasing. It has become clear that they
are not simply linear cascades but consist of branching pathways as well as feedback
loops and cross-talking signals. The duration and strength of these signals in each cell
type affects the outcome. Different MKKKs can phosphorylate the same MEKs, and
the same MAPKs can be activated by more than one MEK. In addition, kinases along
MAPK pathways have several family members and alternatively spliced forms whose
specific functions are far from clear [Lewis et al., 1998]. As an example of the ERK-
pathway complexity, PKCδ  activates Raf/MEK/ERK independently of Ras [Ueda et
al., 1996], and MEK1/2 can be activated independently of Ras/Raf by Mos and
MKKK1 [Lange-Carter et al., 1993; Posada et al., 1993]. Further, MEK-independent
activation of MAPKs by phosphoinositol 3-kinase and protein kinase C has been
observed [Grammer and Blenis, 1997]. Feedback loops along the ERK pathway are
also likely to exist, and indeed, Sos and Raf phosphorylation by MEK have been
detected [Holt et al., 1996; Wartmann et al., 1997]. The existence of various
phosphatases regulating MAPK pathway kinases generates an additional level of
complexity [Lewis et al., 1998]. An interesting model for control of signal specificity
has emerged recently, in which specific scaffolding proteins are required to bring
together the correct kinases and their relevant substrates [Schaeffer et al., 1998].
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Other pathways activated by Ras
Although the Raf/ERK pathway seems to be an important cascade utilized in cell
growth, differentiation and transformation by Ras, other pathways have been recently
elucidated (see Figure 5). In some cell types, Raf alone is unable to cause
transformation similar to Ras-transformation [Oldham et al., 1996], but requires
complementary pathways for full transformation. In addition, Ras-mutants lacking
Raf-binding still show cell transformation capacity [Khosravi-Far et al., 1996].
Ras-related small GTPase proteins of the Rho-family as well as Ral and Rap1, are
implicated in Ras-activated pathways [Bos, 1998; Campbell et al., 1998] (see Figure
5). The members of the Rho family of small GTPases (e.g. RhoA-E and Rac1-2) are
involved in actin cytoskeleton organization but they are also required in SAPK
pathways as well as in cell cycle progression through G1 [Hall, 1998]. Constitutively
active mutants of Rac1 and RhoA cause weak cellular transformation that is enhanced
by Raf and Ras, whereas dominant negative Rac1 or RhoA inhibits Ras-
transformation, indicating that these GTPases have functions downstream of Ras
[Khosravi-Far et al., 1995]. Rho also prevents induction of p21 by Ras, which causes
cells to enter the S-phase [Olson et al., 1998]. Rho-family proteins activate SAPK
pathways more efficiently than ERKs and may connect Ras to these pathways
[Minden et al., 1995], but also to cytoskeletal events that seem to be regulated at least
partly via SAPK-independent pathways [Hall, 1998]. Although the mechanisms of
interaction between Ras and Rho-proteins are not known, they may include the
binding of Ras to p190 RhoGAP directly or via p120 RasGAP [Campbell et al.,
1998], or signaling through Ral GTPase. Ras is linked to Ral by binding to Ral
guanine nucleotide dissociation stimulators (GDSs) which increase the activity of Ral
[Hofer et al., 1994]. Ral enhances Ras-transformation whereas dominant negative Ral
inhibits Ras-transformation [Urano et al., 1996]. Furthermore, dominant negative Ras
prevents Ral activation by insulin and EGF [Wolthuis et al., 1998]. Downstream
effectors of Ral may include Rho GTPases, but for the most part the effectors as well
as results of the signaling are still unknown [Bos, 1998]. Ras and Rap1 have very
similar effector domains, and they both can bind Raf and RalGDS [Bos, 1998].
Whether Rap1 is inhibitory towards Ras or has Ras-effector functions is still under
study.
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Of the known RasGAPs, p120GAP seems to function not only as a negative regulator
of Ras but also as a Ras effector (see Figure 5). p120GAP binds to Ras by its C-
terminus and accelerates Ras inactivation, whereas various domains in the N-terminus
can mediate binding to p190 RhoGAP, Src and other molecules [Tocque et al., 1997].
Another strong Ras downstream effector candidate is phosphoinositol 3-kinase
(PI3K), involved both in mitogenic and antiapoptotic events [Khwaja et al., 1997;
Campbell et al., 1998]. Ras is needed for full PI3K-activation by growth factors
[Rodriguez-Viciana et al., 1994], and PI3K mediates the antiapoptotic effects of Ras
[Khwaja et al., 1997]. However, depending on the activating stimuli, PI3K may act
also upstream of Ras [Fantl et al., 1992]. Recent yeast two hybrid screenings have
also come up with new Ras-effector candidates AF6 (ALL-1 fusion partner 6)
[Kuriyama et al., 1996] and Rin1 (Ras interaction/interference gene 1) [Han et al.,
1997] that compete with Raf for Ras-binding. At present, the true relevance and
functions of these proteins are not known. In addition, free radicals are implicated as
signaling components in the Ras pathway [Lander et al., 1995a; Lander et al., 1995b;
Irani et al., 1997; Deora et al., 1998].
RAS
Rin1 NF1 AF6
p190GAP
p120GAP
Rho/Rac JNK
MEKK
SEK
Raf
MEK
ERK
Ral
RalGDS PI3K
AKT ?
? ?
??
Figure 5. Ras-activated pathways. Modified from Campbell et al. [1998], Khosravi-Far et al
[1998]. The relevance and downstream targets of most Ras effectors are obscure (?). The most
convincing evidence exists for activation of the Raf/MEK/ERK pathway by Ras (bold). AF6,
ALL-1 fusion partner 6; AKT, serine/threonine kinase named Akt or protein kinase B
[Khwaja et al., 1997]; p120GAP, p120 RasGAP; p190GAP, p190 RhoGAP; Rin1, Ras
interaction/interference gene 1; SEK, SAPK kinase.
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Retinoblastoma tumor suppressor
Functions of the retinoblastoma protein (Rb)
The retinoblastoma gene (RB) is a prototype of tumor suppressor genes, the loss-of-
function of which precedes cancer formation. The retinoblastoma protein (Rb)
functions during the cell cycle especially at the G1 restriction point regulating S-phase
entry [Bartek et al., 1997]. Further, it has been shown to inhibit apoptosis [Lee et al.,
1992; Almasan et al., 1995; Haas-Kogan et al., 1995] as well as to function in cellular
senescence [Futreal and Barrett, 1991] and differentiation [Gu et al., 1993], probably
by inducing growth arrest.
Mice lacking both alleles of RB (RB-/-) are nonviable and exhibit defective
hematopoietic and neuronal differentiation and massive neuronal cell death [Jacks et
al., 1992; Lee et al., 1992]. Heterozygous mice (RB+/-) survive but have higher
incidences of pituitary and thyroid tumors arising from somatic inactivation of the
only functional RB allele [Jacks et al., 1992]. In addition, the differentiation of
myotubes and adipocytes is defective when RB is lacking [Mulligan and Jacks, 1998].
In humans with RB+/- background, inactivation of the remaining functional RB allele
is required for childhood retinoblastoma to arise [Hooper, 1998]. Inactivation of both
alleles is seen also in sporadic tumors such as osteosarcomas and soft tissue sarcomas
[Reissmann et al., 1989], small cell lung carcinomas [Harbour et al., 1988], breast
[Lee et al., 1988], bladder [Reznikoff et al., 1996] and prostate carcinomas [Brooks et
al., 1995], as well as in leukemia [Furukawa et al., 1991]. Reconstitution of functional
RB in RB-deficient cells reverts tumorigenic properties either with or without
concomitant growth inhibition suggesting that the tumor suppressive functions of Rb
do not necessarily operate via growth arrest [Huang et al., 1988; Bookstein et al.,
1990; Wang et al., 1994].
Regulation of Rb-activity by phosphorylation
Rb is a nuclear phosphoprotein which undergoes cell cycle-dependent
phosphorylation steps [Buchkovich et al., 1989; Chen et al., 1989]. It is active in its
hypophosphorylated form during the G0 and G1 phases of the cell cycle preventing
premature S-phase entry. When cells approach the S phase, Rb is inactivated by
phosphorylation of multiple residues permitting cell cycle progression [Buchkovich et
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al., 1989]. At least 16 possible phosphorylation sites have been identified located both
in the N- and C-terminal parts of the protein [Wang et al., 1994] (see Figure 6).
Although sequential phosphorylation steps and specific kinases involved in the
process in vivo are unclear, it seems that in the G1 phase, Cdk4/cyclin D and
Cdk6/cyclin D complexes phosphorylate some residues of Rb, followed by
subsequent phosphorylation by Cdk2/cyclin E [Lundberg and Weinberg, 1998].
During the later stages of the cell cycle Rb is possibly phosphorylated by Cdk2/cyclin
A and Cdc2/cyclin A and B complexes [Sherr, 1996].
Binding of Rb to its targets
Phosphorylation steps regulate the binding of Rb to other cellular partners. The major
protein binding domain of human Rb is a so-called A/B pocket that spans residues
379-572 (pocket A) and 646-772 (pocket B) with an intervening insert domain
necessary for the proper three-dimensional structure of the pocket [Wang et al., 1994]
(see Figure 6). Many transcription factors (e.g. Elf-1, PU.1, ATF-2), viral
oncoproteins, as well as histone deacetylase interact with Rb via the A/B pocket (see
Table 1) [Wang et al., 1994; Luo et al., 1998], whereas a larger A/B pocket, which
contains some C-terminal residues in addition to the A/B pocket, is required for
effective binding of E2F transcription factors and D-type cyclins [Qin et al., 1992;
Dowdy et al., 1993; Ewen et al., 1993]. In addition to the A/B pocket, Rb contains a
so-called C-pocket in its C-terminus (residues 772-928) that binds the c-Abl tyrosine
kinase as well as Mdm-2, known to downregulate p53 [Welch and Wang, 1993; Xiao
et al., 1995]. Recently, proteins binding to the N-terminus have also been identified,
including Raf [Wang et al., 1998] and Mcm7 (minichromosome maintenance gene 7)
involved in DNA replication [Sterner et al., 1998]. Although the A/B pocket is
insufficient by itself, it is necessary for growth suppression by Rb [Qin et al., 1992].
Stressing the importance of the A/B pocket for Rb-functions, most identified RB
mutations affect its three-dimensional structure [Kaye et al., 1990; Wang et al., 1994].
Further, Rb can be inactivated also by viral oncoproteins such as SV40 large T
antigen, adenovirus E1A or papilloma virus E7 that bind to the A/B pocket and
replace E2F [Wang et al., 1994]. The A/B pocket seems to function as a
transcriptional repressor, whose activity is blocked upon Rb phosphorylation [Chow
et al., 1996]. Indeed, stepwise phosphorylation of Rb probably serves to coordinately
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inactivate specific Rb-functions. Phosphorylation of serine 795 abolishes growth
suppression by Rb [Connell-Crowley et al., 1997] and phosphorylation of serine 780
disrupts E2F-binding [Kitagawa et al., 1996]. Phosphorylation of serines 807 or 811
dissociates c-Abl, and of threonines 821 or 826 detaches SV40 large T antigen
[Knudsen and Wang, 1996].
N A ID B C
1 379 572 646 772 928
** * * * * * ** * * * ****
Figure 6. The protein structure of Rb. Modified from Wang et al. [1994]. The amino acids
are numbered starting from the N-terminus of Rb. A; a part of the A/B pocket region, B; a
part of the A/B pocket region, C; the C pocket, ID; insert domain, N; the N-terminal domain.
Asteriscs; potential phosphorylation sites starting from the N-terminus: Thr 5, Ser 230, Ser
249, Thr 252, Thr 356, Thr 373, Ser 567, Ser 608, Ser 612, Ser 780, Ser 788, Ser 795, Ser
807, Ser 811, Thr 821, Thr 826 (Ser; serine, Thr; threonine).
Rb and cell cycle control
The core events in G1 cell cycle progression are thought to be Rb phosphorylation and
inactivation by active Cdk/cyclin complexes. This liberates the transcription factor
E2F from Rb and leads to expression of genes required in S-phase entry [Bartek et al.,
1997]. The E2F transcription factor family consists of six proteins (E2F1-6) of which
E2F1-3 bind Rb most readily during G1/S progression [Dyson, 1998]. In cycling cells
the DNA-binding activity of E2F3 is shown to correlate best with the cyclic
expression of E2F target genes [Leone et al., 1998]. E2Fs function as heterodimers
with DP-family proteins, and the prevalence of different complexes in different
tissues, as well as their specificity towards different target genes, vary [DeGregori et
al., 1997; Dyson, 1998]. E2F complexes can function as transcriptional activators or
repressors, as well as transactivation inert complexes, the functions of which are
regulated by binding of additional proteins, in G1 especially of Rb [Dyson, 1998]. Rb
can passively inhibit functions of E2F by forming inert complexes that are unable to
activate transcription [Dyson, 1998]. Alternatively, Rb-E2F complexes may bind
DNA and actively repress E2F-regulated transcription [Dyson, 1998]. E2F target
genes include cell cycle regulators such as Cyclin E, Cyclin A, CDC2 and CDK2 and
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genes regulating DNA replication, e.g. DNA polymerase α, thymidine kinase,
dihydrofolate reductase, ORC1 (origin recognition complex 1), CDC6 and MCM
genes 2 and 6 [Su et al., 1995; Wuarin and Nurse, 1996; Dyson, 1998]. p19ARF [Bates
et al., 1998] and MYC [Oswald et al., 1994] are also E2F-targets that take part in
regulation of cell cycle progression.
Since RB-/- cells do not totally lack the G1 restriction point control, additional cell
cycle regulators are required [Herrera et al., 1996]. Further, since Rb has multiple
binding partners, it is unlikely that E2F is critical for all Rb functions [Mulligan and
Jacks, 1998; Sellers et al., 1998]. Rb can regulate transcription by directly binding to
other transcription factors discussed earlier (see also Table 1). Rb can also affect
transcription by binding to proteins involved in regulation of chromatin structure such
as the Brg-family proteins [Dunaief et al., 1994] or histone deacetylase [Luo et al.,
1998], or regulate DNA replication via Mcm7 [Sterner et al., 1998]. Binding of Rb to
c-Abl inhibits Abl-functions needed in cell cycle progression [Welch and Wang,
1993], whereas binding to Mdm2 may modulate p53 functions [Xiao et al., 1995].
Recently, Rb has been also shown to regulate the activities of RNA polymerases I, II,
and III, which links Rb to more general aspects of cell growth regulation [Bartek et
al., 1996].
The Rb protein family
Since Rb and E2F represent a whole family of proteins that may overlap functionally,
analysis of their true functions and importance is complicated. Currently the Rb-
family consists of Rb, p107 and p130 [Mulligan and Jacks, 1998]. They are most
homologous in their A/B pocket region, being able to bind similar target proteins
including viral oncoproteins and E2Fs. Outside the pocket region, however, obvious
dissimilarities suggest also unique functions for each family member. The
independent roles of p107 or p130 in cell cycle regulation and tumor suppression are
still unknown at present. Individual Rb-family members seem to bind different E2F
transcription factors (see Table 1) and affect transcription of a different set of E2F-
regulated genes [Hurford et al., 1997]. Unlike Rb, p107 and p130 bind E2F5 as well
as cyclins A and E, but not E2F1-3 or D-type cyclins [Mulligan and Jacks, 1998]. In
addition, they bind E2F4 more avidly than Rb. p107 binds uniquely to Myc and
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represses Myc-regulated transcription [Beijersbergen et al., 1994], but does not
interact with Mdm2 or histone deacetylase [Mulligan and Jacks, 1998].
Binding protein           Putative function                                       Rb     p107  p130
Abl Tyrosine phosphorylation + ND ND
ATF2 Regulation of transcription + ND ND
Brg Remodeling of chromatin + + +
C/EBP Regulation of transcription: lineage specific + + ND
cyclin A, E Regulation of Cdk-activity - + +
cyclin D Regulation of Cdk-activity + - -
E2F1-E2F3 Regulation of transcription:growth control + - -
E2F4 Regulation of transcription:growth control + + +
E2F5 Regulation of transcription:growth control - + +
Elf1 Regulation of transcription: lymphoid + ND ND
HBP1 Regulation of transcription: repression + - +
HDAC1 Remodeling of chromatin + - ND
Mdm2 Inhibition of p53 + - ND
Myc Regulation of transcription:growth control - + -
MyoD1 Regulation of transcription: myogenic control + + ND
Myogenin Regulation of transcription: myogenic control + + ND
PU.1 Regulation of transcription: lymphoid + ND ND
TAF250 Regulation of transcription: RNA Pol II + ND ND
TFIIIB Regulation of transcription: RNA Pol III + ND ND
UBF Regulation of transcription: RNA Pol I + - ND
Table 1. Rb-family binding proteins. Modified from Mulligan and Jacks [1998]. See also
the references below. Abl, Abelson tyrosine kinase; ATF, bZIP transcription factor [Kim et
al., 1992]; Brg, human homologue of yeast SNF/SWI proteins [Dunaief et al., 1994]; C/EBP,
CCAAT/enhancer binding protein [Timchenko et al., 1999]; Elf1 and PU.1, lymphoid-
specific Ets-family transcription factors; HBP, HMG (high-mobility group)-box protein [Shih
et al., 1998]; HDAC, histone deacetylase; Mdm2, murine double minute-2; MyoD1 and
Myogenin, muscle-specific transcription factors; TAF, TATA-binding protein-associated
factor; TFIIIB, transcription factor IIIB; UBF, upstream binding factor [Voit et al., 1997]; pol,
polymerase; ND, not determined.
RB-family knockout studies have shown overlapping functions and complementation
among the Rb proteins as well as unique activities [Mulligan and Jacks, 1998].
Especially, all Rb-functions can not be complemented by other family members since
RB-/- mice are not viable [Jacks et al., 1992]. p107-/- or p130-/- mice, in contrast,
exhibit no obvious developmental defects nor are they cancer-prone whereas
p107/p130 double mutants die perinatally and exhibit excessive chondrocyte
proliferation and respiratory insufficiency [Mulligan and Jacks, 1998]. However, the
conclusions of the results in mice are not directly applicable to humans or other
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species. For example, the absence of retinoblastomas in mice heterozygous for RB
along with the existence of severe retinal dysplasia in RB+/-p107-/- mice indicate
differential regulation of retinal development by RB-family members in mouse and
man [Jacks et al., 1992; Mulligan and Jacks, 1998].
p21 cyclin kinase inhibitor
p21 inhibits the activity of Cdks
The human p21CIP1/WAF1 gene (also called CAP20, PIC1, SDI1 and MDA-6) is located
in chromosome 6p21.2 and its sequence is well conserved among mammalians [El-
Deiry et al., 1993]. The structure and functions of p21Cip1/Waf1 protein (p21) are also
well conserved [El-Deiry et al., 1993]. p21 was initially characterized as a subunit of
Cdk/cyclin/PCNA complexes with an unknown function [Xiong et al., 1993b]. Later
on, it was shown to be upregulated by p53 tumor suppressor [El-Deiry et al., 1993] as
well as to inhibit the activity of various Cdks and to arrest cells in the G1 phase
[Harper et al., 1993; Xiong et al., 1993a]. p21 inhibits avidly complexes of Cdk2,
Cdk3, Cdk4 and Cdk6, but is a weaker inhibitor of Cdc2 and Cdk5 and does not
associate with Cdk7/cyclin H (CAK) at all [Harper et al., 1993; Harper et al., 1995].
p21 binds to Cdks and cyclins via separate N-terminal sequences [Nakanishi et al.,
1995; Chen et al., 1996], but only simultaneous binding to both brings about its
inhibitory activity [Fotedar et al., 1996]. Inhibition may be achieved by competing
with the substrates for Cdk/cyclin binding [Adams et al., 1996], but also by
preventing the Cdk-activation by CAK [Aprelikova et al., 1995] or Cdc25A
phosphatase [Saha et al., 1997].
p21 and cell cycle regulation
p21 levels are regulated during the cell cycle. After an initial peak by serum
stimulation, p21 amounts decrease towards the S phase [Li et al., 1996]. Its binding to
cyclin D complexes does not vary significantly during the cycle but increased binding
to cyclin A and B complexes is observed in early S and G2, respectively [Li et al.,
1994b]. In addition to G1 arrest, p21 is shown to retard S-phase progression and arrest
cells in the G2 phase [Ogryzko et al., 1997; Medema et al., 1998]. Apart from
inhibiting the Cdks, p21 may also enhance their kinase activity. Active, p21-bound
Cdk/cyclin complexes have been detected [Zhang et al., 1994]. In addition, LaBaer et
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al. [1997] have shown that binding of p21 as well as p27Kip1 (p27) to Cdk4 and cyclin
D increases Cdk4 activity by promoting Cdk4/cyclin D complex assembly. In cells
lacking both p21 and p27, this assembly is highly deficient [Cheng et al., 1999]. In
light of these results, it has been postulated that one p21 molecule per complex may
activate, while two or more p21 molecules inhibit the Cdk activity. However,
structural studies on p27 suggest that only one p27 molecule binds to one Cdk/cyclin
complex [Morgan, 1995], and recently it was also shown that one bound p21 molecule
can efficiently inhibit Cdk activity [Hengst et al., 1998]. Additionally, in vivo studies
of Cai and Dynlacht [1998] suggest that the kinase activity of Cdk2/cyclin A
complexes free of p21 is considerably higher than that of complexes bound to p21.
They also showed that in G1 a lot of p21 is in the unbound form and postulated that
there is an excess of p21 in resting cells, some of which binds to and inactivates Cdk-
complexes, the surplus being free. At the border of G1/S, the amount of Cdk/cyclin
complexes exceeds the amount of p21, allowing kinase activity and S-phase entry
[Cai and Dynlacht, 1998]. The results do not, however, exclude the possibility that
p21 could at some point promote kinase activity.
Cdk-regulation, although important, is not the sole function of p21. Uniquely among
the p21-family members, p21 can bind to the proliferating cell nuclear antigen
(PCNA) which is a subunit of DNA polymerases δ and ε [Luo et al., 1995]. PCNA-
mediated DNA-replication activity is inhibited by p21 binding while PCNA-mediated
DNA repair is not [Li et al., 1994a]. Recent studies suggest that p21 regulates normal
cell cycle progression primarily via Cdk-inhibition [Ogryzko et al., 1997], whereas
the PCNA-interaction would serve as a coordinator of DNA replication and repair e.g.
after DNA damage [Li et al., 1996].
p21 in differentiation, senescence and transformation
p21CIP1/WAF1 has been characterized as a melanoma differentiation-associated gene
(MDA-6) [Jiang et al., 1995], and thereafter it has been implicated in both initiation
and maintenance of cellular differentiation. p21 is induced independently of p53
during differentiation of muscle cells, keratinocytes, leukemia cells and many other
cell types [Halevy et al., 1995; Parker et al., 1995; Schwaller et al., 1995; Di Cunto et
al., 1998]. During keratinocyte differentiation, an initial peak of p21 is observed, after
which exogenous expression of p21 inhibits differentiation [Di Cunto et al., 1998].
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Although expression of p21 in leukemia cells induces megakaryocytic differentiation
[Matsumura et al., 1997], in most cases p21 seems to be required for the initial growth
arrest but not for the later stages of differentiation [Di Cunto et al., 1998; Erhardt and
Pittman, 1998]. p21 has also been suggested to play a role in cellular senescence
[Serrano et al., 1997]. It was originally identified as a senescent cell-derived inhibitor
(SDI1), upregulated in senescent but not in young cells [Noda et al., 1994].
Inactivation of p21 is shown to cause immortalization [Brown et al., 1997]. p21 is also
induced during premature senescence induced by Ras in primary cells [Serrano et al.,
1997].
Although no p21 mutations have been found in human malignancies [Shiohara et al.,
1994], p21 has been shown to counteract cellular transformation. In most cases, it
fights transformation by arresting cells [Givol et al., 1995]. However, it has also been
shown to inhibit transformation without blocking cell proliferation, in other words,
separately from its growth arresting functions [Michieli et al., 1996].
p21 induction by p53
Coinciding with the identification of p21 as a Cdk inhibitor, p21 was found to be
transcriptionally induced by the p53 tumor suppressor gene product [El-Deiry et al.,
1993] which is thought to be a central regulator of growth arrest and apoptotic
responses after cellular stress and DNA damage [Levine, 1997]. p53 induces p21 after
DNA damage by γ-irradiation and during cellular senescence thereby causing growth
arrest [Dulic et al., 1994; Noda et al., 1994; Serrano et al., 1997]. p21-/- fibroblasts
show abnormally high saturation density in culture and exhibit a reduced although not
completely abrogated capacity for growth arrest by γ-irradiation [Deng et al., 1995].
Unlike p53-knockout mice, p21 knockouts are not tumor-prone and, in contrast to p53
-/- cells, p21-/- cells retain normal apoptotic and mitotic spindle checkpoint functions
[Deng et al., 1995]. The results imply that p21 executes at least part of the growth
suppressive functions of p53 and highlight the importance of p21 in regulation of cell
cycle progression in normal and stress situations.
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p53-independent regulation of p21
Although p21 induction after γ-irradiation seems to be p53-dependent, p21 can be
upregulated independently of p53 by various stimuli. In most adult and embryonic
tissues and during differentiation, p21 expression does not require p53 [Macleod et
al., 1995; Parker et al., 1995]. Cell cycle dependent oscillation of p21 protein occurs
also in p53-deficient cells [Sheikh et al., 1994], as well as its induction by serum and
various growth factors [Michieli et al., 1994] (discussed below). Further, apart from γ-
irradiation, many DNA-damaging stimuli as well as oxidative stress and UV-radiation
induce p21 and cause growth arrest even in the absence of p53 [Johnson et al., 1994;
Russo et al., 1995; Haapajärvi et al., 1999]. Thus, a broad spectrum of inducers other
than p53 suggests p53-independent functions for p21.
Transcriptional and posttranscriptional regulation of p21
p53 activates p21 transcription via two p53 consensus binding sites located at -2285
and -1394 from the transcription initiation site [El-Deiry et al., 1993; Macleod et al.,
1995]. In addition, other stimuli including serum, growth factors, hormones,
intracellular signaling molecules and tumor suppressors regulate p21 transcription
independently of p53 (see Figure 7). TGF-β causes transcriptional activation of p21
through a TGF-β responsive element (TRE) that overlaps one of the multiple
consensus binding sites for the Sp1 transcription factor family located near the
transcription start site [Datto et al., 1995b]. TGF-β functions by increasing the
transactivation activity of Sp1 [Datto et al., 1995a; Li et al., 1998]. Progesterone,
NGF, phorbol esters and ocadaic acid induce p21 through the multiple Sp1 binding
sites [Biggs et al., 1996; Yan and Ziff, 1997; Owen et al., 1998], which are also
required for p21 induction during keratinocyte differentiation by calcium [Prowse et
al., 1997]. Transcriptional activation of p21 during thrombopoietin-induced leukemia
cell differentiation as well as in interferon-γ-, EGF- and FGF-induced growth arrest is
likely to occur via STAT-binding sites located at -4232, -2557 and -692 [Chin et al.,
1996; Matsumura et al., 1997; Johnson et al., 1998]. Dexamethasone induces p21 via
a C/EBP (CCAAT/enhancer binding protein) binding site at -1263 [Cha et al., 1998;
Cram et al., 1998], vitamin D3 via a DRE (vitamin D response element) site at -771
[Liu et al., 1996b], and retinoic acid receptor via a RARE (retinoic acid response
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element) sequence at -1203 [Liu et al., 1996a]. Raf and MEK also induce p21
transcription [Liu et al., 1996c; Sewing et al., 1997] although the promoter sequences
they utilize are not known. Elements responsible for serum-induction of p21 are
speculated to be the Ets-binding sites overlapping with the p53-binding sites [Macleod
et al., 1995; Funaoka et al., 1997]. The transcription factor E2A binds to E-box
sequences located proximal to the TATA-box [Prabhu et al., 1997], while Ap2 binds
to its consensus sequence located at -103. This site is also used in some cases for p21
transcription regulated by ocadaic acid and phorbol esters [Zeng et al., 1997]. The
tumor suppressor BRCA1 arrests cells by activating p21 transcription via sequences
within -143- -93 of the p21 promoter [Somasundaram et al., 1997]. In addition, the
WT1 tumor suppressor induces growth arrest via increasing p21 mRNA levels
although the role of transcriptional activation is unknown [Englert et al., 1997].
Figure 7. Schematic drawing of the p21 promoter and its different response elements.
Modified from Gartel and Tyner [1999]. Ca, calcium; C/EBP, CCAAT/enhancer binding
protein; IL, interleukin; INF, interferon; OA, ocadaic acid; p300, cAMP-response element
binding protein (CBP/p300) [Owen et al., 1998]; PMA, phorbol-12-myristate-13-acetate; PR,
progesterone receptor; RAR, retinoic acid receptor; TPA, 12-O-tetradecanoyl-phorbol-13-
acetate; TPO, thrombopoietin. The transcription factors Ap2, E2A, Sp1/3 and STATs are also
presented. T, TATA-box; circles with an asterisk, p53-binding sites, which overlap distally
with the Ets-binding sites [Macleod et al., 1995]; black circles, STAT-binding sites; white
circles, Sp1 binding sites, of which the proximal five are numbered. Numbering of the base
pairs correlates with the transcription start site at +1.
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Transcriptional regulation is not the sole mechanism for p21 upregulation. For
example, although serum stimulation induces p21 protein to equal levels in both
p53+/+ and p53-/- cells, the p21 mRNA levels reach 10-fold higher amounts in
p53+/+ cells, implying posttranscriptional regulation of p21 in cells lacking p53
[Macleod et al., 1995]. In addition, oxidative and genotoxic stress seem to regulate
p21 posttranscriptionally [Esposito et al., 1997; Butz et al., 1998] as well as do
ocadaic acid, phorbol esters, vitamin D3, ultraviolet-radiation and oncoprotein E7
[Schwaller et al., 1995; Zeng and El-Deiry, 1996; Gorospe et al., 1998; Jian et al.,
1998].
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OUTLINE OF THE STUDY
Malignant transformation of normal cells requires cooperative activation of growth
promoting factors and inactivation of growth inhibiting factors eventually generating
unrestricted proliferative capacity, the basis of tumorigenesis. We therefore undertook
analyses of cellular interactions between proteins that positively and negatively
regulate cell proliferation. In these studies the c-Ha-Ras oncoprotein and growth
factors were used as models for transforming and proliferative stimuli, the effects of
which were analyzed on the negative cell cycle regulators retinoblastoma (Rb) and
p21 CKI (p21).
At the time I began my investigation, knowledge of Ras downstream effectors and
connections of Ras to cell cycle regulation were scant. In the first study (I), our aim
was to elucidate whether the tumor suppressor and cell cycle regulator Rb could
prevent Ras transformation in immortal mouse fibroblast cells. This was indeed
observed, without effects on cell growth (I). At that time, mechanisms for interactions
between Rb and Ras remained purely speculative due to a lack of knowledge of other
downstream targets of Ras. During the further studies, however, cyclin D1 was
suggested as a candidate molecule linking Ras and the cell cycle [Filmus et al., 1994;
Liu et al., 1995; Winston et al., 1996]. This, along with a new experimental model of
conditional Ras-expression, gave us a new perspective for elucidation of events
underlying interactions between Rb and Ras both at the level of growth factor
signaling and the cell cycle (II). Further, increasing knowledge of Ras-signaling via
mitogen-activated protein kinase (MAPK) pathways [Crews et al., 1992], and
identification of new proteins, CKIs, as crucial inhibitors of Cdk/cyclin complexes
[Harper et al., 1993] led us to studies involving Ras and p21 CKI regulation (III), as
well as regulation of p21 CKI by growth factors via Ras-activated pathways (IV).
These studies clarify some effects of proliferative and transforming signals on the cell
cycle machinery in cultured fibroblasts. Some nuclear events observed after mitogenic
stimulation may be required for execution of the signal, while other nuclear reactions
may serve to counteract and eventually silence the signal. Both of these actions have
crucial roles balancing normal cell proliferation, and their deregulation promote
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carcinogenesis. Therefore, the analyses of the interplay between proliferative stimuli
and the cell cycle are highly relevant.
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MATERIALS AND METHODS
Cell culture, transfections and soft agar assays
Cell culturing was performed at +37°C in a humidified 5% CO2 atmosphere. Cells
used in the experiments were NIH 3T3 mouse fibroblasts (ATCC CRL 1658) and
their derivatives, COS-7 African Green monkey kidney cells transformed by Simian
virus 40 (ATCC CRL 1651, received from Prof. A. Vaheri, University of Helsinki)
and HaCaT human immortalized keratinocytes (received from O. Saksela, University
of Helsinki). COS-7 and HaCaT cells were cultured in Dulbecco's modified Eagle's
medium (D-MEM) containing 10% fetal calf serum (FCS, Gibco-BRL). In addition,
HaCat cells required glutamine (0.3 mg/ml), penicillin (100 IU/ml) and streptomycin
(0.1 mg/ml). NIH 3T3 cells were cultured in D-MEM containing 10% newborn calf
serum (NBCS, Gibco-BRL). Stable NIH 3T3 clones expressing wild-type or mutant
RB (RB and FK clones, respectively) were generated by transfection (Lipofectin,
Gibco-BRL) with plasmids pcDneo containing the neomycin resistance gene and
pSG5RB/FK containing full-length wild type or mutant human RB cDNA,
respectively (kindly provided by J. DeCaprio, Dana-Faber Cancer Institute, Boston,
Massachusetts). The transfectants were maintained under selection of 0.4 mg/ml G418
(Geneticin, Gibco). RB and FK clones were further transfected by calcium phosphate
precipitation [Graham and van der Eb, 1973] with the hygromycin B resistance gene
(pY3) and the human Ha-Ras(Val-12) oncogene either under its own promoter
(pGEJ6.6, clones F/T-5 and F/T-7 in I) or under Moloney murine leukemia LTR
promoter (LTR(P)rasA, clones F/T-8 in I) and cultured in the presence of G418 and
0.2 mg/ml hygromycin B (Calbiochem). pGEJ6.6 and LTR(P)rasA plasmids were
kindly provided by I. Västrik and K. Alitalo (University of Helsinki).
For conditional expression of oncogenic Ha-Ras(Val-12), NIH 3T3 or NIH 3T3
RB4.6 cells were transfected (LipofectAMINE, Life Technologies Inc.) with the
plasmids pHβINLSneo and pSVlacOras (kind gifts from N. Denko, University of
Cincinnati Medical Center, Cincinnati, Ohio) [Liu et al., 1992], and suitable clones
were selected for resistance to G418, soft agar growth and transformed morphology in
the presence of isopropyl β-D-thiogalactoside (IPTG, Promega) that activates Ha-
Ras(Val-12) expression. The transfectants were cultured under G418-selection (0.4
mg/ml). For conditional expression of dominant negative Ras, NIH 3T3 cells were
transfected by calcium phosphate precipitation with the plasmids pHβINLSneo and
pSVlacO-Ras(Asn-17) and selected and cultured in the presence of 0.4 mg/ml G418.
pSVlacO-Ras(Asn-17) was generated by cloning a 1.1 kb insert containing Ras(Asn-
17) received from L. Feig (Tufts University, Boston, Massachusetts) into pSVlacO
vector.
Soft agar assays were used to analyze the cellular transformation by Ras (I). Ras-
transfected cells were plated in 0.34% agar on top of 0.5% agar, both containing 10%
NBCS and 10% tryptose phosphate broth in D-MEM. After two weeks, colonies with
15 cells or more were counted. Soft agar growth was also utilized to select
conditionally Ras-expressing NIH 3T3 clones (II, III). After transfection with the
plasmids pHβINLSneo and pSVlacOras, NIH 3T3 cells were transferred to 0.34%
agar containing 10% FCS, 10% tryptose phosphate broth, 0.6 mg/ml G418 and 20
mM IPTG in D-MEM, and plated on 0.5% agar containing 10% FCS, 10% tryptose
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phosphate broth and 10 mM IPTG in D-MEM. After two weeks, colonies were picked
and analyzed further.
Chemicals and growth factors
The following chemicals were used in cell culture studies: compactin, inhibitor of Ras
isoprenylation (Fluka), cycloheximide, inhibitor of protein synthesis (Sigma),
isopropyl β-D-thiogalactoside (IPTG), inducer of conditional Ras expression
(Promega), PD 098059, MEK1(/2) inhibitor (Calbiochem), calyculin A, protein
phosphatase 2A inhibitor and a weak protein phosphatase 1 inhibitor (Calbiochem),
genistein, tyrosine kinase inhibitor (Sigma), bisindolylmaleimide, protein kinase C
inhibitor (LC-Laboratories), chelerythrin, protein kinase C inhibitor (Sigma),
staurosporine, kinase inhibitor (LC-Laboratories) and N-acetylcysteine, an inhibitor of
free radical formation (Sigma).
The following growth factors were used: human recombinant EGF (30 ng/ml,
Calbiochem), human recombinant FGF-2 (3-7 ng/ml, Calbiochem), human natural
PDGF (5-10 ng/ml, Calbiochem), TGF-β1 (5-250 pM, extracted from human
platelets).
Protein analyses
Immunofluorescence
For analysis of the amount and cellular localization of human Rb protein, cells were
grown on glass cover slips, fixed with 100% cold methanol on ice, permeabilized with
0.5% Nonidet P-40 (NP-40, Calbiochem) and immunostained with monoclonal anti-
human Rb antibody (PMG3-245, Pharmingen) followed by rhodamine-conjugated
rabbit anti-mouse antibody (Dako). The final detection was obtained by UV
illumination with an Olympus BH-2 microscope.
Immunoblotting
Cells were washed twice with TBS (25 mM Tris-HCl, pH 8.0 and 150 mM NaCl)
followed by lysis with buffer containing 25 mM Tris-HCl pH 8.0, 120 mM NaCl,
0.5% NP-40, 4 mM NaF (Sigma), 100 µM Na3VO4 (Sigma), 100 KIU/ml aprotinin
(Sigma), 1 mM phenylmethyl sulfonylfluoride (PMSF, Sigma) and 10 µg/ml
leupeptin (Sigma). For Ras-detection (in II), cells were lysed with 50 mM Tris-HCl
pH 8.0, 150 mM NaCl, 1% NP-40, 1% Triton X-100 (Sigma), 1 mM PMSF, 100
KIU/ml aprotinin. Equal amounts of lysates were run in 7.5-15% SDS-polyacrylamide
gels (SDS-PAGE) and transferred to Immobilon P membrane (Millipore) in buffer
containing 25 mM Tris-HCl pH 8.5, 192 mM glycine, 20% methanol and 0.01% SDS.
The membranes were blocked with 3% BSA (Fr. V, Sigma) (I-II) or with 5% milk
(III-IV) for one hour at room temperature (RT). For protein detection the following
monoclonal antibodies were used: anti-human Rb (PMG3-245, Pharmingen), anti-Ras
(Ab-1, Oncogene Science), anti-p53 (Pab240, Pharmingen) and anti-p27 (Kip1,
Transduction Laboratories). Anti-p21 (13436E, Pharmingen), anti-cdk2 (M2, Santa
Cruz Biotechnology), anti-cdk4 (C-22, Santa Cruz Biotechnology), anti-cdk6 (C-21,
Santa Cruz Biotechnology), anti-cyclin D1 (H-295, Santa Cruz Biotechnology) and
phospho-specific anti-MAPK (V667A, Promega) antibodies were polyclonal. As the
conjugates peroxidase-conjugated rabbit anti-mouse antibody (for Ras in I and IV,
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Rb) or biotinylated rabbit anti-mouse IgG followed by peroxidase-conjugated
streptavidin (Ras in II-III, p53, p27) were used. Polyclonal antibodies were detected
with swine anti-rabbit IgG, except for p21 (in III, Fig. 1) and phosphorylated ERK1/2,
for which biotinylated goat anti-rabbit IgG and streptavidin-biotinylated peroxidase
(Amersham) were used. Except for the streptavidin-biotinylated peroxidase, the
conjugates were from Dako. The final detection was accomplished with enhanced
chemiluminescence (ECL, Amersham).
Immunoprecipitation
Immunoprecipitation was performed from either metabolically labeled or unlabeled
samples. For metabolic labeling the cells were incubated for 6 hours with 125 µCi/ml
35S-labeled methionine/cysteine (Promix, Amersham) in Eagle's minimal essential
medium (MEM) free of methionine and cysteine supplemented with 10% dialyzed
FCS. For immunoprecipitation, the cells were washed twice with TBS and lysed with
50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% NP-40, 50 mM NaF, 1 mM Na3VO4, 1
mM PMSF, 1 mM dithiothreitol (DTT, Sigma), 100 µg/ml leupeptin, 100 µg/ml
soybean trypsin inhibitor (SBTI, Sigma) and 100 µg/ml cysteine proteinase inhibitor
L-trans-epoxysuccinic acid (E64, Sigma). Thereafter the lysates were pre-cleared with
GammaBind G-Sepharose (Pharmacia Biotech) for 2 hours at +4°C, and then
precipitated with specific antibodies and GammaBind G-Sepharose for one hour each,
washed and run in SDS-PAGE. Radioactive gels were fixed with 10% acetic acid and,
after signal amplification with Enlightning (Du Pont), dried and exposed. Unlabelled
samples were transferred to Immobilon P membrane and analyzed according to the
immunoblotting protocol outlined above.
mRNA analysis by Northern blotting
For analysis of mRNA levels, poly(A)+ mRNA was isolated using oligo(dT) cellulose
(Collaborative Research Inc. or Calbiochem) and run in 1% agarose gels containing
formaldehyde. mRNAs were thereafter transferred to Hybond-C extra membrane
(Amersham) in buffer containing 3 M NaCl and 0.3 M sodium citrate, pH 7.0
(20xSSC) and detected by probing with cDNA inserts labeled with [α32P]dCTP by
Random priming (Ready-to-Go, Pharmacia). Hybridizations were carried out at 42°C
in hybridization solution containing 50% formamide, 4xSSC, 5xDenhardts, 10 mM
Tris-HCl pH 7.4, 2.5 mM EDTA, 2.5 mM Na4P2O7 x 10H2O, 0.2% SDS, 0.5%
ssDNA and 10% dextran sulphate. Probing with labeled glyceraldehydephosphate
dehydrogenase (GAPDH) was used to correct loading differences. Filters were
quantitated by Phosphoimager analyzer.
DNA analysis by Southern blotting
DNA analysis was carried out by extracting DNA with guanidium-HCl/sodium
acetate using Bowtell's method [Bowtell, 1987] and thereafter by digesting with
restriction enzymes BamHI or EcoRI. Digested samples were run in agarose gels in
TBE buffer (Tris base 8.9 mM, boric acid 8.9 mM and 2 mM EDTA pH 8.0) followed
by transfer to Hybond-C extra membrane in 20xSSC and probing with [α32P]dCTP-
labeled cDNA inserts as indicated above.
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cDNA probes
The following inserts were isolated, labeled and used in Northern and Southern
blottings: human full-length RB (pSG5RB, from J. DeCaprio, Dana-Faber Cancer
Institute, Boston, Massachusetts), Ha-RAS (pGEJ6.6, from K. Alitalo and I. Västrik,
University of Helsinki, Finland), mouse CDK4 (pCMJ3cdk4, from C. Sherr, St. Jude's
Childrens Hospital, Memphis, Tennessee), Cyclin D1 (pHsCYCD1-H123, from D.
Beach, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York), TIMP-2
(537-bp cDNA, from U. Saarialho-Kere, University Hospital of Helsinki, Helsinki,
Finland), mouse ODC (pODC16, from O.A. Jänne, University of Helsinki, Finland),
E2F-1 (pSP72-pRBAP-1, from W. Kaelin, Dana-Faber Cancer Institute, Boston,
Massachusetts), human c-MYC (pSVT-c-myc, from K. Alitalo, University of Helsinki,
Finland) and mouse p21WAF1/CIP1 (pCMW35, from B. Vogelstein, Johns Hopkins
University, Baltimore, Maryland).
p21-promoter constructs and luciferase assay
Transcriptional activation of p21 was analyzed by transfecting the cells by calcium
phosphate precipitation with the pGL2 Basic vector (Promega) containing the firefly
luciferase gene under control of the p21 promoter. Co-transfections with β-
galactosidase (CMV-β-gal) or Renilla luciferase (pRL-TK, Promega) expression
vectors were used to correct differences in transfection efficiency. Lysates were
prepared and luciferase activities measured by the Luciferase Assay System
(Promega) for CMV-β-galactosidase co-transfected samples, or by the Luciferase
Dual Reporter Assay System (Promega) for pRL-TK co-transfected samples, using a
DCR-1 luminometer (Digene Diagnostics).
The following p21 promoter luciferase constructs were received from M. Datto and
X.-F. Wang (Duke University Medical Center, Durham, NC): p21p (human full-
length 2.4 kb p21 promoter), ∆1.1 (proximal 1.4 kb of p21 promoter), ∆ 1.9 (proximal
500 bp of p21 promoter), ∆ 2.3 (proximal 200 bp of p21 promoter), Sma (proximal
110 bp of p21 promoter), Sma∆1 (proximal 61 bp of p21 promoter), 93-S (proximal
93 bp of p21 promoter), 93-S mut 2-6 (different mutants of 93-S promoter) and pGL2
Basic (no promoter) (III) [Datto et al., 1995b]. To generate luciferase constructs with
multiple mutant p21 promoter sequences (93-S mut 2+3, mut 2+4, mut 3+4 and mut
2+3+4, see sequences in III), two sequential PCR-reactions were carried out. In the
first PCR reaction, a primer containing the desired mutant sequences was used for the
following templates: 93-S mut 2 (for mut 2+3 and mut 2+4), mut 3 (for mut 3+4), or
mut 2+3 (for mut 2+3+4). In the second PCR, the product of the first PCR-reaction
was used as a primer for templates mut 3 (for mut 2+3), mut 4 (for mut 3+4 and mut
2+4) and mut 3+4 (for mut 2+3+4). The products of the second PCR were verified by
sequencing, and then cloned into the 93-S promoter construct.
Electrophoretic mobility shift assays (EMSA)
To analyze the binding of Sp1 transcription factors to the p21 promoter, we produced
wildtype and mutant oligonucleotides spanning the sequence of Sp1 binding site 2 in
the p21 promoter (see sequences in III). The complementary oligonucleotides were
annealed and endlabeled with [γ32P]ATP (Amersham) by T4 polynucleotide kinase
(New England Biolabs) for one hour at 37°C. Nuclear extracts were prepared as
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described in Andrews and Faller [1991]. 1.2 ng of labeled oligonucleotide was
incubated with 5-10 µg of nuclear extract in an equal volume of buffer containing 40
mM Hepes-KOH pH 7.9, 50 mM KCl, 0.2 mM EDTA, 20% glycerol (Sigma), 4 mM
MgCl2, 1 mM DTT, 0.05% NP-40, 4 mM spermidine (Sigma) and 10 µg/ml poly
dI:dC (Pharmacia Biotech) for 30 minutes at +4°C. The specificity of DNA-protein
complexes and the presence of Sp1 and Sp3 transcription factors were analyzed by
incubating nuclear extracts with unlabeled wild-type or mutant oligonucleotides or
with 0.5 µg of anti-Sp1 (IC6, Santa Cruz Biotechnology) or anti-Sp3 antibodies (D-
20, Santa Cruz Biotechnology) at RT for 10 minutes before addition of the labeled
oligonucleotide. The reactions were run in 4.5% acrylamide gel containing 5%
glycerol in TBE buffer, followed by drying and exposing of the gel.
Cell cycle analyses
FACS-analysis
For analysis of cell cycle stages, cells were trypsinized and fixed with ice-cold
methanol at -20°C. Fixed cells were incubated at 37°C in phosphate buffer PBS and
50 µg/ml RNaseA (Sigma) for 30 minutes, followed by overnight DNA-staining with
50 µg/ml propidium iodide (Sigma) at 4°C. Flow cytometry was performed by
FACScan (Becton-Dickinson) using the CellFIT Cell Cycle Analysis program.
5-bromo-2'-deoxy-uridine incorporation
To determine the fraction of replicating cells, cells were cultured on cover slips in the
presence of 2 µg/ml 5-bromo-2'-deoxy-uridine for 1-2 hours (5-BrdU, Sigma), then
fixed with 3.5% paraformaldehyde, permeabilized with 0.5% NP-40 and denaturated
with 1.5 N HCl. The cells were thereafter immunostained with monoclonal anti-5-
BrdU antibody (Amersham) and rhodamine-conjugated rabbit anti-mouse antibody.
For staining of all nuclei Hoechst 33258 (2 µg/ml, Sigma) was used. The fraction of
anti-5-BrdU-stained nuclei was determined under UV illumination with an Olympus
BH-2 microscope.
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RESULTS AND DISCUSSION
Human wild-type Rb prevents c-Ha-Ras transformation in NIH 3T3 cells (I, II)
Oncogenic Ras is able to transform many immortal cell lines including NIH 3T3 cells
[Stacey and Kung, 1984]. However, we show here that expression of human Rb in
NIH 3T3 cells prevents cellular transformation by H-Ras(Val-12) as studied by soft
agar growth and cell morphology (I). H-Ras(Val-12) transformed 65% of the NIH
3T3 cell colonies emerging after transfection, while the amount of transformed
colonies was reduced to 37% in the presence of human wildtype Rb (I). Similar
results were obtained in transfections with both genomic promoter and LTR-driven H-
Ras(Val-12). Studies with stable Rb-clones expressing genomic H-Ras(Val-12) (EJ6.6
clones, 26 clones studied) or LTR-driven H-Ras(Val-12) (LTR clones, 29 clones
studied) showed that a normal phenotype correlated with high levels of exogenous Rb
and low levels of Ras protein, whereas -with a few exceptions- most transformed
EJ6.6 and LTR clones exhibited decreased levels of Rb and high levels of Ras. The
results imply that Rb is able to prevent Ras-transformation in NIH 3T3 cells and that
transformation depends on high Ras levels but also on decreased levels of wildtype
Rb, especially in EJ6.6 clones. This is further supported by the fact that the EJ6.6
clones gradually transformed in culture with simultaneous upregulation of Ras protein
and downregulation of Rb (discussed below).
Mutual regulation of exogenous Rb and c-Ha-Ras expression in NIH 3T3 cells (I, II)
The majority of the phenotypically normal (flat) EJ6.6 clones (8 out of 10 propagated
clones) gradually transformed during the mean of 45 days of culturing, with a
concomitant decrease in Rb and increase in Ras protein levels (I). These clones were
denoted as convertants. In contrast, the morphology of the flat LTR clones remained
stable (I). Although the results suggest that regulation of Rb and Ras expression might
be coupled and affect cell morphology, the mechanisms of the regulation are unclear.
The data imply either repression of Ras-expression by Rb that is lost by Rb
downregulation, or indicate Ras-repression of Rb. In the converted EJ6.6 clones, high
Rb levels were not restored by a short-term blockage of Ras-functions with compactin
(I), suggesting that downregulation of Rb could be a primary event, Ras being
upregulated only thereafter. In other words, Rb might function as a repressor of Ras
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expression. The fact that the LTR clones, with artificial promoter sequences for Ras,
did not convert during culture (I) gives further support to this conclusion. Indeed, Rb
has been shown to regulate transcription via Sp1 transcription factors [Udvadia et al.,
1993] and might therefore downregulate Ras transcription via Sp1 binding sites
present in the Ras promoter [Ishii et al., 1986]. The opposite possibility, i.e. that Ras
regulates exogenous Rb at the level of transcription is unlikely, since Rb-expression is
driven by the strong SV40 promoter (I). This alternative was also excluded by
chloramphenicol acetyltransferase (CAT) assays in which Ras did not affect the
expression of SV40 promoter-driven CAT (II, data not shown). However,
downregulation of Rb by posttranscriptional means by Ras is possible.
In the convertant clones, a mechanism for gradual changes in Rb and Ras protein
levels and transformation could include selection and outgrowth of subpopulations of
cells with growth advantage due to high Ras and low Rb levels (I). Although similar
growth rates in both primary and converted clones argue against this theory, the
possibility could not be excluded by using a cellular model with constitutive
expression of Rb and Ras (I). One reason for the generation of cell clones with
conditional Ras expression was to obtain better tools to study the role of selection as
well as other possible mechanisms regulating Ras and Rb levels (II). Conditional
expression of Ras in Rb-expressing NIH 3T3 cells led to a decrease in Rb protein with
simultaneous morphological transformation suggesting rather Rb-regulation by Ras
than the opposite (II). The new approach also showed that the Ras-effect on Rb levels
was rapid, occurring in hours, therefore ruling out the possibility of selection (II).
However, it cannot be excluded that two different mechanisms operate in the two
different cellular models, especially since in the conditional expression system Ras
expression is driven by an artificial promoter.
Taken together, the data suggest that H-Ras(Val-12) downregulates exogenous Rb in
NIH 3T3 cells thereby inducing cellular transformation (I, II). The downregulation is
unlikely to be accomplished by transcriptional regulation (II, data not shown).
Simultaneously with the decrease in Rb protein, also a decrease in RB mRNA was
observed, pointing to posttranscriptional regulation of Rb that may be achieved e.g. by
decreased mRNA stability (II). However, part of the downregulation may occur via
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regulation of translation efficiency and/or protein stability that were not analyzed in
these studies.
Pathways regulating Rb by c-Ha-Ras (I, II)
The short-term blockage of Ras activity by compactin in the convertant clones did not
lead to upregulation of Rb (I). This suggests that Ras may not directly repress Rb but
rather activate mediators that are not readily inhibited by Ras inactivation. To study
the Ras-regulation of Rb in a more controlled way, conditionally Ras-expressing cells
with high Rb expression were generated (II). The results with this model
demonstrated that Ras downregulates Rb rather fast but also supported the idea of the
indirect nature of the Rb decrease by Ras (II). First, the Ras-induced decrease in Rb
protein and mRNA levels did not occur in low serum but the response was restored by
growth factors EGF, FGF-2, TGF-β1 and PDGF (II). Second, when Ras-expressing
cells were supplied with fresh culture medium, high Rb protein levels were re-
established although the Ras levels remained high (II). In the light of the data, we can
speculate on theoretical connections between Ras and Rb. Growth factors and their
activated pathways may be required to maintain high levels of Rb, while Ras
expression interferes with these pathways at some point (see Figure 8a). On the other
hand, Ras could enhance growth factor signals that lead to Rb-downregulation e.g. by
producing growth factor autocrine loops or by mediating or co-activating growth
factor cascades (see Figure 8b). One of the two theories or their combination may be
relevant since Ras is a mediator of many growth factor signals [Satoh et al., 1992], but
is also able to generate autocrine loops of growth factor signaling as well as affect
receptor composition on the cell surface (see review of the literature) [Dickson et al.,
1987; Pironin et al., 1992; Paasinen-Sohns and Hölttä, 1997]. Although Ras did not
downregulate Rb in low serum, it was still able to transform the cells (II). This
suggests that either the slightly lower basal level of Rb observed in low serum is not
enough to prevent Ras-transformation or that serum-dependent factors in addition to
Rb are required to maintain a normal phenotype in response to Ras.
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Figure 8. Possible pathways for Ras-regulation of Rb in transformation of NIH 3T3
cells. a, Ras blocks growth factor-activated pathways that are required to maintain high Rb
levels. b, Ras enhances growth factor-regulated pathways that downregulate Rb. Decreased
levels of Rb are then unable to counteract the Ras transformation.
Mechanisms for inhibition of c-Ha-Ras transformation by Rb (I, II)
It cannot be easily concluded by which mechanism Rb ultimately prevents Ras
transformation. However, we have observed that exogenous Rb is able to prevent
cellular transformation by also large T antigen of the simian virus 40 [Pitkänen et al.,
1993]. Since the large T antigen transforms cells by directly binding and inactivating
Rb [Ludlow et al., 1989], exogenous Rb probably counteracts its effects by binding
competition, demonstrating a mechanism different from what we see with Rb and
Ras. Further, it has been shown that ectopic expression of p16 CKI prevents Ras-
transformation by arresting cells in G1 [Serrano et al., 1995]. In our studies, Rb did
not result in growth arrest. The results therefore suggest an other, yet unidentified
means for inhibition of Ras-transformation, which are not coupled with the cell cycle
arresting functions of Rb.
Relevance of mutual regulation of Rb and Ras (I, II)
Rb-expressing cells are gradually transformed by Ras since Ras is able to block Rb-
functions by downregulating Rb expression in a posttranscriptional manner (II). Since
both activation of growth stimulators and inactivation of growth inhibitors occur
during tumorigenesis, it is not unexpected that Ras leads to the deregulation of
negative growth regulators. Indeed, Ras expression has also been shown to promote
inactivation of the tumor suppressor p53 [Lu et al., 1992; Peacock and Benchimol,
1994]. Downregulation of Rb is particularly understandable since there is strong
evidence that the cell cycle effects of Ras and Rb are linked by cyclin D. Activation of
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Ras increases expression of cyclin D thereby leading to enhanced phosphorylation and
inactivation of Rb and, finally, to the S-phase entry [Albanese et al., 1995; Bartec et
al., 1997]. In agreement with this, inactivation of Ras leads to G1-arrest of Rb-
expressing fibroblasts via reduction of cyclin D1 and hypophosphorylation of Rb,
while cells lacking Rb are not growth arrested [Mittnacht et al., 1997; Peeper et al.,
1997]. Yet another and more direct link between Rb and the Ras pathway has
emerged in recent studies. Raf-1, a downstream effector of Ras, was shown to interact
physically with Rb in the nucleus after mitotic stimulation in cell culture conditions
and, at least in vitro, phosphorylate and inactivate Rb [Wang et al., 1998]. Rb
phosphorylation was not affected by Ras in our studies (I, II). However,
downregulation of Rb, which counteracts Ras-effects at the level of cell cycle control,
could be one mechanism for Ras to enhance its transforming and mitogenic
properties.
c-Ha-Ras-regulation of other target genes in Rb-expressing NIH 3T3 cells (II)
Many aspects of cell cycle regulation that were obscure at the time of the first study
(I), including the fact that Ras is linked to the cell cycle via cyclin D1, were revealed
later [Filmus et al., 1994; Liu et al., 1995]. In the second study, we therefore analyzed
mRNA levels of several key regulators of the cell cycle. Ras has been shown to affect
expression of its target genes by e.g. the Ap1 and Ets families of transcription factors
(see the review of the literature) [Galang et al., 1994; Roussel, 1998], but it also
regulates some of its targets, such as fibronectin, ODC, syndecan-1 and TGF-α,
posttranscriptionally [Hölttä et al., 1988; Kirjavainen et al., 1993; Chandler et al.,
1994; Berkowitz et al., 1996].
The analyses of TIMP-2 and ODC mRNA as well as fibronectin levels, with known
responses to Ras, were carried out to test the functionality of the conditional Ras-
expression system as well as the specificity of the other observed changes. TIMP-2
mRNA and fibronectin were downregulated upon Ras expression as expected (II and
data not shown) [Chambers and Tuck, 1993], whereas ODC mRNA levels were not
induced by Ras, probably due to the high basal level of ODC mRNA in the Rb4.6
clone. However, ODC-induction was observed in NIH 3T3 cells upon conditional Ras
expression (Kivinen, unpublished observations). These results support the
applicability of the cellular model for analyses of Ras-responses.
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Downregulation of Rb by conditional Ras expression seemed to occur
posttranscriptionally (II). Rb-expressing cells exhibited also increased basal mRNA
levels of MYC that were slightly decreased upon conditional Ras expression and
downregulation of Rb (II). Myc is essential for normal cell cycle progression and is
shown to overcome Rb-induced growth arrest [Goodrich and Lee, 1992]. Depending
on the cellular context, MYC may be either downregulated or upregulated by Rb
[Pietenpol et al., 1991; Batsche et al., 1994], and also the transcription factor E2F,
which is under negative control of Rb, is shown to induce MYC transcription [Oswald
et al., 1994]. In addition, MYC expression seems to require partly functional Ras-
signaling [Kerkhoff et al., 1998]. In our cell model, MYC mRNA seemed to be under
the positive control of Rb since the high basal level was downregulated upon Rb
repression. However, less direct mechanisms are also possible. For example, TGF-β is
shown to repress MYC expression independently of Rb [Zentella et al., 1991], which
could be achieved in theory by indirect autocrine loops initiated by Ras. The
relevance of the observed MYC regulation is not known.
Rb-expressing cells exhibited an increased level of Cyclin D1 mRNA that was not
further modulated either by conditional Ras expression or downregulation of Rb (II).
According to the literature, both Ras and Rb can induce Cyclin D1 [Filmus et al.,
1994; Muller et al., 1994; Liu et al., 1995]. The high basal level of Cyclin D1 mRNA
seen in our studies may be a result of exogenous Rb expression. In contrast, the lack
of Cyclin D1 mRNA downregulation in response to the Rb decrease may be caused by
concomitant increase in Ras levels or otherwise aberrant Cyclin D1 regulation in the
presence of constitutive Rb expression. In NIH 3T3 cells lacking exogenous Rb,
cyclin D1 was inducible by Ras, also leading to increased binding of cyclin D1 to
Cdk4 (III). Since exogenously expressed Rb was shown to be phosphorylated in a cell
cycle dependent manner [Pitkänen et al., 1993], higher amounts of cyclin D1 may be
required for phosphorylation of the large Rb pool.
The mRNA level of CDK4 was not affected in Rb-expressing cells by Ras (II), nor
were the protein levels of Cdk2, Cdk4 or Cdk6 in NIH 3T3 cells (III). This is
understandable since expression of Cdks does not vary greatly during the cell cycle or
after mitogenic stimuli although their activities are modulated [Sherr, 1996]. E2F
mRNA was unaffected by Ras as well (II, data not shown). However, the amount of
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E2F protein free of Rb-binding rather than the amount of mRNA is critical for E2F
function (see review of the literature). Similarly to the results in NIH 3T3 cells (III,
discussed later), p21CIP1/WAF1 mRNA was not regulated by conditional Ras expression
in the Rb-expressing cells, although at the protein level a slight induction was
observed (Kivinen, unpublished observations).
Mutant Rb enhances c-Ha-Ras-transformation in NIH 3T3 cells (I)
Ras-transfections to NIH 3T3 cells expressing mutant Rb protein (the FK mutant, see
below) [Kaye et al., 1990] showed that the amount of Ras-transformed cell colonies
increased from 65% to 85% in the presence of mutant Rb (I). This result suggests that
this particular Rb mutant is able to slightly promote Ras-transformation. In FK clones
transfected with Ras, none of the morphologically normal clones had detectable Ras
expression, while the transformed phenotype correlated with increased Ras-
expression. The levels of mutant Rb protein remained unchanged regardless of
morphology (I). Although the FK clones were initially more prone to Ras-
transformation than NIH 3T3 or Rb4.6 cells, the clones that remained phenotypically
normal after Ras-transfection did not transform during culture (I). The reasons for the
lack of gradual Ras-upregulation and transformation in FK clones may include
defective expression of exogenous Ras as well as lack of regulation pathways
functioning between Ras and the wildtype Rb.
It is known that Rb can bind to various cellular proteins and that it is phosphorylated
at multiple sites which regulate its activity and functions (see review of the literature).
It is therefore likely that different Rb mutants do not function identically. The mutant
Rb used here (FK) originates from a small-cell lung cancer cell line and harbors a
single base pair substitution from cysteine to phenylalanine at codon 706 disrupting
the A/B pocket [Kaye et al., 1990]. This leads to deficient Rb phosphorylation and the
inability to bind the viral oncoproteins SV40 large T antigen, E1A and E7, as well as
to decreased DNA affinity [Kaye et al., 1990; Kratzke et al., 1992; Stirdivant et al.,
1992]. Since also E2Fs and histone deacetylase interact with Rb through the A/B
pocket, their functions may be altered. Binding of this particular Rb-mutant to Mdm2
and c-Abl is, however, shown to be intact [Wang et al., 1994; Xiao et al., 1995]. A
functional A/B pocket is required for the tumor suppressive activity of Rb as well as
for inhibition of polymerase activities [Cavanaugh et al., 1995; White et al., 1996],
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and it has been shown to form a transcriptional repressor motif [Chow et al., 1996].
Mechanisms for enhanced transformation capacity may include deficient interactions
with A/B pocket-binding proteins or increased interactions with partners that bind to
the intact regions, e.g. to the C-pocket or the N-terminus of mutant Rb (see Figure 6 in
the review of the literature). Conformational changes caused by the point mutation
may also lead to novel protein or DNA interactions that ultimately promote
transformation. Indeed, changes in composition of the Rb-complexes can lead to
surprisingly different effects. For example, in different cell types transcription of Rb
target genes may be either stimulated or inhibited by wildtype Rb, probably due to
alternative Rb-complexes regulating transcription [Kim et al., 1991; Batsche et al.,
1994]. Although we can only speculate about the mechanisms by which the used Rb-
mutant enhances Ras-transformation, the same mutant was also able to slightly
enhance transformation by the large T antigen [Pitkänen et al., 1993].
p21 CKI is induced by c-Ha-Ras expression (III)
p21 CKI is inducible by growth arrest but also by mitogenic signals (see review of the
literature). Our results show that c-Ha-Ras induces expression of p21 by both
transcriptional and posttranscriptional means (III). Posttranscriptional induction
occurs in conditionally Ras-expressing NIH 3T3 cells, which display constitutively
increased levels of Ras and in which the magnitude of further Ras-induction is
moderate. In contrast, the transcriptional activation of p21 is seen in both NIH 3T3
and COS-7 cells transiently expressing high-level of Ras.
Transcriptional regulation of p21 by c-Ha-Ras (III)
In addition to Ras, transcriptional regulation of p21 has been seen by many other
factors including the tumor suppressors p53 [El-Deiry et al., 1993] and BRCA1
[Somasundaram et al., 1997], growth factors TGF-β [Datto et al., 1995b] and NGF
[Yan and Ziff, 1997], vitamin D [Liu et al., 1996b], retinoic acid [Liu et al., 1996a],
glucocorticoids [Cha et al., 1998], progesterone [Owen et al., 1998], as well as by
serum [Liu et al., 1996c]. Raf and MEK, downstream effectors of Ras, also activate
p21 transcription but the promoter sequences they require have not been analyzed
[Liu et al., 1996c; Sewing et al., 1997]. Transcription factors such as STATs [Chin et
al., 1996; Matsumura et al., 1997], C/EBPα [Cram et al., 1998], E2A [Prabhu et al.,
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1997], Ets-family proteins [Funaoka et al., 1997], Ap2 [Zeng et al., 1997] and Sp1/3
[Prowse et al., 1997; Li et al., 1998] also regulate p21 transcription.
We localized the p21-promoter sequences required for Ras-inducible transcriptional
regulation near the transcription start site from -110 bp forward in both NIH 3T3 and
COS-7 cells (see Figure 7). This region contains a cluster of five Sp1 consensus
binding sites (numbered 1-5 in III and in Figure 7), one Ap2 site, a TGF-β responsive
element, two E-boxes and a TATA-box [Datto et al., 1995b; Prabhu et al., 1997; Zeng
et al., 1997]. Closer analysis in COS-7 cells identified the Sp1 binding sites 2 and 4 in
this region crucial for the Ras-effect. In a similar way, different Sp1 binding sites or
their combinations within the Sp1-cluster are required for p21 induction by
progesterone [Owen et al., 1998], ocadaic acid and phorbol esters [Biggs et al., 1996],
NGF [Yan and Ziff, 1997], TGF-β [Li et al., 1998] and by calcium during
keratinocyte differentiation [Prowse et al., 1997].
Both Sp1 and Sp3 transcription factors were shown to bind the Sp1 binding site 2 in
COS-7 cells, although we observed no enhancement of their DNA-binding activity by
Ras (III). Similar results have been obtained by TGF-β and NGF which upregulate the
transactivation function of Sp1 without increasing its DNA binding [Yan and Ziff,
1997; Li et al., 1998]. In general, Sp1/3-mediated transcription can be regulated
through changes in Sp1/3 protein levels, DNA-binding and transactivation activity, of
which the last mentioned may be modulated by at least O-glycosylation and
phosphorylation [Roos et al., 1997; Black et al., 1999]. For example, serum
stimulation is shown to promote cell cycle-dependent Sp1 phosphorylation and to
increase Sp1-mediated transcription without changing the DNA-binding activity. This
effect was suggested to result from changes in association of the phosphorylated Sp1
to other regulatory proteins [Black et al., 1999]. In a similar way, Ras might directly
affect Sp1/3 activity. Ras may also indirectly regulate molecules binding to Sp1/3,
such as inhibitors of Sp1 transactivation activity [Murata et al., 1994]. Further,
changes in the cooperative action of transcription factors binding to the separate Sp1
binding sites could be one regulatory mechanism, which may have passed unnoticed
here, since the performed EMSA assay demonstrates binding to one Sp1 site only
(III). Lastly, binding of unidentified transcription factors or other Sp1 family members
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that recognize the same GC-rich sequences cannot be excluded [Hagen et al., 1992;
Imataka et al., 1992].
Posttranscriptional regulation of p21 by c-Ha-Ras (III)
Although the transient Ras-expression strongly activated the p21 promoter,
conditional Ras-expression in NIH 3T3 cells seemed to bring about
posttranscriptional regulation of p21 (III). This was suggested by the lack of p21
promoter activation and of significant induction in p21 mRNA in the stable cell clones
(III). During metabolic labeling more labeled p21 was detected in Ras-expressing
cells without simultaneous increase in p21 protein stability. Therefore, enhanced
translation from mRNA to protein was suggested as a possible mechanism for p21
induction in these cells (III). More and more evidence is emerging for
posttranscriptional regulation of p21 by various stimuli including oxidative and
genotoxic stress, ocadaic acid and phorbol esters [Macleod et al., 1995; Schwaller et
al., 1995; Zeng and El-Deiry, 1996; Esposito et al., 1997; Zauberman et al., 1997;
Butz et al., 1998]. In these cases, changes in mRNA or protein stability as well as
translation efficiency may be involved. Indeed, protein upregulation may be achieved
more economically via posttranscriptional regulation than by promoting transcription,
and in many cases of increased p21 transcription, an additional posttranscriptional
component of induction cannot be excluded. For example, p53 has been recently
shown, besides transcriptional activation, to increase p21 mRNA stability [Gorospe et
al., 1998]. In addition to p21, the level of p27 CKI is also regulated
posttranscriptionally during the cell cycle [Pagano et al., 1995], and Ras
downregulates p27 protein stability [Takuwa and Takuwa, 1997] and, along with
RhoA, mediates p27 degradation by PDGF [Weber et al., 1997]. Our earlier studies
also suggest that Ras regulates Rb levels posttranscriptionally (II).
The relevance of dual regulation of p21 by Ras
Our results indicate that Ras may influence p21 both transcriptionally and
posttranscriptionally. However, since the transcriptional regulation was analyzed
using artificial p21-promoter luciferase constructs, it would be informative to analyze
the transcription of endogenous p21CIP1/WAF1. Although we observed that transient Ras
expression increases the protein levels of endogenous p21 in both NIH 3T3 and in
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HaCaT cells that contain mutant p53 (see Figure 9), more extended analyses of the
p21 mRNA levels after transient Ras expression would be valuable in the future. The
reasons for the different regulation of p21 in the two cellular systems are undefined.
However, constant Ras expression in conditionally Ras-expressing NIH 3T3 cells may
have permanently affected p21 regulation. On the other hand, variations in the
amplitude of Ras-induction achieved in the two expression systems could explain the
differing control of p21 expression. For example, after a certain threshold level of
transcription, Ras may turn to upregulate p21 posttranscriptionally. However, in both
cases the same mission -upregulation of p21- is accomplished. Consistently, Raf and
MEK downstream of Ras also induce p21 transcriptionally [Liu et al., 1996c; Sewing
et al., 1997].
Neo NeoEJ6.6 EJ6.6UVC UVC
NIH 3T3 HaCaT
p53
p21
Figure 9. Transient expression of oncogenic Ras induces p21 protein levels in NIH 3T3
cells and in HaCaT cells. NIH 3T3 cells (the left panels) and HaCaT cells (the right panels)
were transfected with pCDneo (Neo and UVC lanes) or Ras-expression vector (EJ6.6 lanes)
constructs by calcium phosphate precipitation [Graham and van der Eb, 1973]. Lysates
were prepared 48 hrs after transfection and analyzed by immunoblotting for p53 and p21
expression. As a positive control for p53 function pCDneo-transfected cells were irradiated
with 25 J/m2 (for HaCaT cells) or 50 J/m2 (for NIH 3T3 cells) ultraviolet C light 6 hrs before
the end of the 48-hr incubation (UVC lanes). HaCaT cells contain mutated, stabilized p53.
Pathways regulating p21 by Ras (III)
According to our present understanding, p53 tumor suppressor is required for p21
induction especially after DNA damage and inhibition of ribonucleotide biosynthesis
[Gartel and Tyner, 1999]. However, with the exception of γ-irradiation, various
genotoxic agents seem to induce p21 effectively also in the absence of p53 [Dulic et
al., 1994; Johnson et al., 1994; Sheikh et al., 1994; Haapajärvi et al., 1999]. Other
stimuli, including hormones and growth factors, upregulate p21 independently of p53
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[Gartel and Tyner, 1999]. Our results suggest that Ras expression induces p21
independently of p53, since Ras did not affect the level or DNA binding activity of
p53 in NIH 3T3 cells (III, data not shown), and it induced p21 also in HaCaT cells
harboring mutant p53 (Figure 9). Further, transcriptional activation of the p21
promoter by Ras did not require p53 consensus binding sites (III). Ras-induced cell
senescence of primary cells is shown to occur concomitantly with induction of p53
and p21 [Serrano et al., 1997]. However, the requirement of p53 in p21 induction was
only assumed in that study. Further, moderate expression of Raf induces p21 via p53
[Lloyd et al., 1997], whereas p21 induction by high-level Raf expression is shown to
be independent of p53 [Sewing et al., 1997; Woods et al., 1997]. The data suggest that
the amplitude of the Ras/Raf pathway activation may determine the nature of p21
upregulation and its dependence on p53 (see discussion below, Figures 10 and 11). In
addition, the different signaling pathway usage observed may be partly explained by
the cell types used.
Ras-induction of p21 by posttranscriptional means occurred via the MAPK-pathway
(III). Other Ras effectors could include cyclin D1, the level of which was increased by
conditional Ras expression (III). Cyclin D1 has been shown to induce p21
transcriptionally [Hiyama et al., 1997] and to regulate Sp1-mediated transcription
[Adnane et al., 1999]. However, the role of cyclin D1 in transcriptional activation of
p21 by Ras was not confirmed here, the same being true also for the MAPK pathway,
although MEK is shown to activate p21 transcription [Liu et al., 1996c]. The role of
Rho was not analyzed here, but Ras could exert the p21-effect by regulating Rho-
functions. Rho is observed to induce S-phase entry by preventing p21 induction by
Ras [Olson et al., 1998], and this repression is mediated via a TGF-β responsive
element and the Sp1 binding site 2 in the p21 promoter [Adnane et al., 1998].
Effects of p21 induction by c-Ha-Ras (III)
p21 cyclin kinase inhibitor is a powerful executor of cell cycle arrest by growth-
inhibiting signals [El-Deiry et al., 1993; Datto et al., 1995b; Englert et al., 1997;
Somasundaram et al., 1997]. Therefore, p21 induction by mitogenic signals such as
oncogenic Ras and growth factors, as seen in our studies, seems somewhat
unexpected. However, similar inductions have been observed in other studies as well.
In primary cells, oncogenic Ras expression induces both p16 and p19ARF [Serrano et
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al., 1997; Palmero et al., 1998] (see Figure 10). p19ARF in turn blocks p53 degradation
which may then cause the p21 induction [Serrano et al., 1997; Palmero et al., 1998].
In addition, p21 can be induced independently of p53 by Ras and Raf (III) [Sewing et
al., 1997; Woods et al., 1997]. High levels of p21 and p16 arrest the cell cycle and
cause cellular senescence [Serrano et al., 1997] (see Figure 10). Consistently,
activation of the MAPK pathway leads to growth arrest of G1-phase cells and
apoptosis of S-phase cells in primary fibroblasts while in cells lacking p53, these
events are greatly diminished and the cells are rather transformed [Fukasawa and
Vande Woude, 1997]. Therefore, the upregulation of p21 by Ras oncoprotein seen in
our study as well as inductions of p53 or p16 observed in other studies may serve to
protect the cells against excessive proliferative signals and malignant transformation
initiated by oncogenic Ras. Indeed, cells can fight inappropriate proliferative signals
by either growth arrest or by apoptosis, and these responses of which must be silenced
for a tumor cell clone to expand. In cells with intact growth regulation, Ras requires
additional co-operating mutations for transformation [Land et al., 1983], while cells
lacking p16 or p53 functions are not growth-arrested but rather transformed by Ras
[Serrano et al., 1997]. Another example of co-operating mutations is seen in the case
of the Myc oncoprotein, the expression of which leads to apoptosis, while the
surviving cells exhibit inactivation of p53 or p19ARF along with the ability to
proliferate [Zindy et al., 1998]. Indeed, it has been suggested that Myc-expression
brings about two signals, one promoting cell cycle entry and the other inducing
apoptosis, and for proliferation to occur, additional signals that block the apoptotic
pathway are required [Hueber and Evan, 1998]. Similarly to Myc, Ras may initiate
both proliferative and growth-arresting signals of which the arrest signals are silenced
by inactivation of p53 or p16, resulting in transformation [Serrano et al., 1997]. In
vivo data also support these findings, since p53-/- mice expressing Ras develop more
aggressive and earlier tumors than mice with wild-type p53 [Hundley et al., 1997].
Further, forced expression of Ras in INK4a-/- mouse keratinocytes (lacking both p16
and p19ARF) generates fast-growing and aggressive melanomas, while in INK4a+/-
cells melanomas emerge later and require loss of the wild-type INK4a [Chin et al.,
1997]. Taken together, induction of p21 and other negative cell cycle regulators may
serve to counteract too strong proliferative and transforming signals such as Ras
expression, while their inactivation may predispose the system to cellular
transformation (see Figure 10 and 11).
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Figure 10. Effects of oncogenic Ras on cell cycle of primary cells. Modified from Palmero
et al. [1998]. In primary cells, expression of oncogenic Ras induces the cyclin kinase
inhibitors p16 and p21 which arrest the cell cycle. p21 may be induced either p19ARF and p53
-dependently or -independently.
Pathways regulating p21 by growth factors (IV)
As seen for Ras, we found that also the growth factors PDGF, FGF-2 and TGF-β1
upregulated p21 expression (IV). However, p21 induction by these factors did not
occur through any linear pathway involving Ras and MEK activation (IV). Ras is
activated by PDGF, FGF and TGF-β [Satoh et al., 1992] while dominant negative Ras
can block the MAPK activation by these factors in many cell types [de Vries-Smits et
al., 1992; Thomas et al., 1992; Hartsough et al., 1996]. In spite of this, in NIH 3T3
cells PDGF required MEK but not Ras for p21 induction, while FGF-2 did not seem
to exclusively need either Ras or MEK (IV). Recently, it has become obvious that
signals propagated by growth factors and their receptors are transmitted to a
complicated network of intracellular pathways. It is therefore likely that their various
effects, including induction of target proteins, are generated via multiple intracellular
cascades. In agreement with this, diverse effects of PDGF and FGF-2 have been
shown to be mediated both via Ras- and MAPK-dependent and independent pathways
[Roche et al., 1996; Kuo et al., 1997; Schweppe et al., 1997; Weber et al., 1997;
Chung et al., 1998]. To further clarify the complicated network of pathways leading to
p21 regulation by growth factors, more extensive analyses of possible downstream
effectors will be needed in the future.
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TGF-β1 upregulated p21 via both Ras and MEK but the induction occurred rather late
and was less prominent than by PDGF or FGF-2 (IV). It is known that there are
several differences in functions of TGF-β and PDGF or FGF-2 that could explain the
observed differences in p21 regulation. Receptors for PDGF and FGF possess tyrosine
kinase activity [Heldin, 1995], and they are strong promoters of fibroblast
proliferation, which is thought to be executed via the MAPK pathway [Wood et al.,
1992; Weber et al., 1997]. In contrast, TGF-β receptors are serine/threonine kinases
that form heterotetramers and initiate growth inhibitory signals in most epithelial and
endothelial cells [Heldin, 1995]. However, TGF-β is unable to arrest, or even
stimulates the growth of mesenchymal cells [Taipale et al., 1998]. TGF-β signals are
mainly transmitted via the Smad protein cascade [Heldin et al., 1997] although
activation of molecules along the MAPK pathway such as Tak1 [Yamaguchi et al.,
1995], Ras and ERKs [Hartsough and Mulder, 1995; Hartsough et al., 1996] have
been observed. The Ras/ERK pathway is especially implicated in TGF-β-induced
growth arrest of epithelial cells that occurs via upregulation of p21 and p27 CKIs
[Hartsough and Mulder, 1995; Yue et al., 1998]. The growth inhibitory effects of
TGF-β are suggested to rely on inhibition of Rb phosphorylation via decreased
Cdk/cyclin activity [Laiho et al., 1990]. In addition, release from TGF-β-induced
growth arrest seems to require Ras as well [Howe et al., 1993]. In NIH 3T3 cells
TGF-β is weakly mitogenic [Kivinen, unpublished observations], and unlike PDGF
and FGF-2, it was unable to induce replication of NIH 3T3 cells in low serum
concentrations (IV). TGF-β also caused late ERK phosphorylation and p21 induction,
suggesting that ERK and p21 are not primary targets of TGF-β, but are rather
activated secondarily. It is known that TGF-β can activate autocrine loops of PDGF,
FGF-2 and other growth factors [Taipale et al., 1998], which could be responsible for
the delayed responses. The p21 induction by TGF-β1 in NIH 3T3 cells may be
connected to the lack of cell cycle entry from the quiescent state (discussed below).
Relevance of p21 induction by growth factors (IV)
In contrast to oncogenic Ras expression, growth factor stimulation is likely to initiate
a more physiological signal in a cell, mimicking normal S-phase entry. p21 levels are
normally rather low in resting cells but are transiently increased by serum and growth
factors during cell cycle progression [Michieli et al., 1994; Li et al., 1996]. This
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induction may be analogous to the p21 induction by FGF-2 and PDGF seen in our
studies and may act as a regulatory step for cells to enter the S-phase in a controlled
way. Indeed, p53-/- cells with low basal p21 expression enter the S-phase more
rapidly than normal cells, while senescent cells have high p21 levels and therefore
exhibit a higher threshold for entry to the cycle [Michieli et al., 1994; Noda et al.,
1994]. In addition, the transient p21 induction by FGF-2 and PDGF may enhance the
assembly of Cdk/cyclin complexes and their activity during S-phase entry [LaBaer et
al., 1997]. All of the growth factors studied here induced p21. The inductions by both
FGF-2 and PDGF were rapid and transient and, although not occurring through
identical cascades, led to the S phase entry. Cells stimulated by TGF-β1 did not enter
the cycle and exhibited slower p21 induction that was executed via a pathway
different from that of the other two growth factors. The data suggests that besides the
activation pathway, the kinetics and the amplitude of p21 induction may determine the
cell cycle effects of these growth factors (see Figures 3 and 11). This is analogous to
the p21 induction by oncogenic Ras.
S phase 
p21 p21
RbP
E2F
Growth factors, Ras
Cdk/cyclin
complexes
TRANSIENT SUSTAINED
Figure 11. Effects of mitogenic signals on p21 and the cell cycle. A strong growth
stimulation by Ras or growth factors leads to sustained induction of p21 which prevents S-
phase entry by inhibiting the Cdk/cyclin complexes and Rb-phosphorylation. A moderate
activation of the mitogenic pathways causes transient p21 induction, activation of the
Cdk/cyclin complex activity, Rb-phosphorylation and the S-phase entry.
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Effects of Rb, p21 and Ras on NIH 3T3 cell growth (I-IV)
Constitutive expression of wildtype or mutant human Rb in NIH 3T3 cells did not
affect cell growth rate in normal serum conditions [Pitkänen et al., 1993], which
allowed us to study the tumor suppressive properties of Rb separately from the growth
regulation. Further, when wildtype (Rb4.6) or mutant (FK) Rb-expressing cells were
transfected with H-Ras(Val-12), the emerging clones -whether morphologically
normal or transformed- had similar growth rates to those of NIH 3T3 control cells (I,
data not shown). Neither did phenotypical conversion during culture increase the
growth rate of these cells (I, data not shown). In addition, conditionally Ras-
expressing Rb4.6 cells exhibited similar growth rates and cell cycle distributions in
the absence and presence of Ras expression (II). Therefore, it can be claimed that in
normal cell culture conditions the inhibition of Ras-transformation by Rb was not
simply a result of growth suppression. When cultured in low serum concentrations,
however, the growth rate of Rb4.6 cells was reduced as compared to mutant Rb-
expressing (FK) or control NIH 3T3 cells [Pitkänen et al., 1993], whereas Rb4.6 cells
expressing Ras retained a high proliferative rate both in high and low serum (II, data
not shown). Since the cells were also transformed in low serum, Ras seemed to be
able to override the growth regulatory and tumor suppressive functions of Rb in the
absence of serum factors (II).
The reasons for the stable growth rate seen in the presence of Rb and Ras can be
speculated about. Since endogenous Rb is functional in NIH 3T3 cells, exogenous Rb
may not be required for cell cycle regulation although it is appropriately
phosphorylated [Pitkänen et al., 1993]. However, under low serum conditions
expression of exogenous Rb protein seems to become important for growth regulation
[Pitkänen et al., 1993]. The introduction of Rb in Rb-deficient tumor cells does not
always repress growth but only tumorigenicity [Bookstein et al., 1990; Pitkänen et al.,
1993; Sogawa et al., 1993], suggesting that indeed these two functions may be
separate. However, the lack of growth arrest of Rb -/- tumor cells by Rb expression
may also be a result of other accumulated mutations that render the cells insensitive to
growth suppression. The NIH 3T3 cells used in our experiments are known to lack
expression of the negative growth regulators p15 and p16 and also p19ARF , which
could explain the defective growth arrest in response to Rb [Linardopoulos et al.,
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1995; Haber, 1997]. However, p15 and p16 are thought to act upstream of Rb,
inhibiting its phosphorylation by Cdk/cyclin complexes [Bartek et al., 1997].
Therefore, it is not known, why expression of exogenous Rb downstream of these
regulators lacks growth suppressive properties. Like p15 and p16, also p19ARF arrests
cell growth [Haber, 1997]. However, p19ARF is not an inhibitor of Cdk/cyclin
complexes but stabilizes and upregulates p53 [Haber, 1997]. The absence of p19ARF
may be one determinant of the defective growth regulation in NIH 3T3 cells by Rb,
although additional unidentified genomic changes may have occurred in these cells.
Such genomic changes in the NIH 3T3 cells may also explain the inability of Ras to
cause cell cycle arrest, a phenomenon seen in many primary cells. In contrast to
primary cells, in immortal cells Ras often promotes S-phase entry (see the review of
the literature). In our studies, however, Ras did not induce cell cycle progression,
which may be due to Rb-expression in Rb4.6 cells (II) but also p21-upregulation (III).
Supporting the latter possibility, Ras-induced p21 inhibited the kinase activity of
Cdk2 (Kivinen, unpublished observations), which may counteract the cell cycle
effects of Ras. In addition, also the amplitude of the mitogenic signal initiated by Ras
may determine whether the cells are growth-arrested or -stimulated (see Figures 3 and
11).
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PERSPECTIVE
The presented studies concentrate on elucidating the effects of Ras- and growth
factor-activated pathways on the cell cycle. During the years 1993-1999, the
complexity of cell signaling from extracellular growth factors to nuclear responses has
grown overwhelmingly. In the future, the relevance of each cascade in different
events and in different cellular contexts needs to be established. Over the years, what
is known of cell cycle regulation has grown as well. The identification of Cdk/cyclin
complexes in the core of the cell cycle machinery and the discovery of small cell
cycle inhibitory proteins of the p21- and INK-families have resolved some of the
mechanisms by which cells respond to both external and internal growth regulation.
Along with other studies, this work sheds light on events starting from growth factor
stimulation and activation of Ras and the mitogen-activated protein kinase pathway,
proceeding to regulation of Cdk-activity by cyclins and CKI proteins, and finally
leading to Cdk-targets such as Rb. The studies showed that Rb-downregulation is
required for cellular transformation by Ras (I), reinforcing the idea of Ras and Rb
counteracting each other along the same pathway. The complexity of the pathway
connecting these two proteins became obvious in the further studies (II). During the
later analyses, p21 CKI, functionally upstream of Rb, was shown to be upregulated
both posttranscriptionally and transcriptionally by Ras (III), further clearing the
picture of cell cycle responses after mitogenic signals. In the fourth study (IV), the
complexity of cascades leading to p21 upregulation by Ras and growth factors was
revealed. The last two studies (III, IV) reinforce the current understanding that many
different stimuli can upregulate p21 cyclin kinase inhibitor via various cascades, and
that, in each cellular context, the amplitude and kinetics of the cascade activation
influence the final cell cycle effects.
In every type of cancer, disturbances of cell cycle regulation are detectable, which
makes the cell cycle studies meaningful and important. The cell cycle is guarded by
two opposing regulatory mechanisms, one breaking the cycle and the other
stimulating it. Since the balance between these "parties" is known to be a necessity for
normal growth, their interactions have been studied here. Some discoveries made of
cell cycle regulation are already in practical use in clinics, giving valuable information
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of diagnosis, prognosis and patients' responses to treatment. In the near future, our
increasing knowledge of tumorigenesis and the cell cycle will hopefully lead to also
more targeted cancer treatments.
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